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Abstract 
In order to assess the true impact of each single enantiomer of pharmacologically active 
compounds (PACs) in the environment, highly efficient, fast and sensitive analytical methods 
are needed. For the first time this paper focuses on the use of ultrahigh performance 
supercritical fluid based chromatography coupled to a triple quadrupole mass spectrometer to 
develop multi-residue enantioselective methods for chiral PACs in environmental matrices. 
This technique exploits the advantages of supercritical fluid chromatography, ultrahigh 
performance liquid chromatography and mass spectrometry. Two coated modified 2.5μm-
polysaccharide-based chiral stationary phases were investigated: an amylose tris-3,5-
dimethylphenylcarbamate column and a cellulose tris-3-chloro-4-methylphenylcarbamate 
column. The effect of different chromatographic variables on chiral recognition is highlighted. 
This novel approach resulted in the baseline resolution of 13 enantiomers PACs (aminorex, 
chloramphenicol, 3-N-dechloroethylifosfamide, flurbiprofen, 2-hydroxyibuprofen, ifosfamide, 
imazalil, naproxen, ofloxacin, omeprazole, praziquantel and tetramisole) and partial resolution 
of 2 enantiomers PACs (ibuprofen and indoprofen) under fast-gradient conditions (<10 min 
analysis time). 
The overall performance of the methods was satisfactory. The applicability of the methods was 
tested on influent and effluent wastewater samples. To the best of our knowledge, this is the 
first feasibility study on the simultaneous separation of chemically diverse chiral PACs in 
environmental matrices using ultrahigh performance supercritical fluid based chromatography 
coupled with tandem mass spectrometry. 
 
Keywords: supercritical fluid based chromatography, polysaccharide-based chiral stationary 
phases, enantiomer resolution, wastewater. 
 
1. Introduction 
Enantiomers of chiral pharmacologically active compounds (cPACs) have become an 
important group of emerging micropollutants in modern environmental research. They often 
exhibit different pharmacokinetics and pharmacodynamics that can result in enantiomer 
dependent toxicity, due to the inherent stereospecifity of biological processes. Despite 
enantiomers of the same PAC exhibiting different levels of biological activity, it is worrying 
that most of them are still commercialized as “racemates” or “racemic mixtures”. The relative 
proportion of a pair of enantiomers is commonly expressed in terms of the enantiomeric 
fraction (EF) (0.5 for racemic mixtures) and provides an insight of the compound’s history, as 
well as pointing to the nature and sources of environmental pollution [1,2]. 
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Unfortunately there is limited understanding of environmental fate and effects of cPACs due 
to the lack of robust analytical methods allowing for simultaneous chiral recognition of cPACs. 
To date, enantioselective separations of cPACs remain a significant challenge, especially for 
environmental samples. High performance liquid chromatography (HPLC) has been the 
preferred choice for chiral separations using chiral stationary phases (CSP), over gas 
chromatography (GC), capillary electrophoresis (CE) or supercritical fluid chromatography 
(SFC) for environmental samples [1–11]. Nevertheless, nowadays the latter has attracted 
growing attention. 
Enantioselective SFC provides fast and high chromatographic efficiency with significantly 
lower solvent consumption than conventional HPLC. SFC makes use of supercritical or 
subcritical CO2-based mobile phases modified with small proportions (1-50 %, v/v) of a co-
solvent that improves the elution strength of the mobile phase for cPACs. The use of CO2, 
which is a nontoxic and nonreactive solvent with low viscosity, allows reduced analysis times 
and lower pressures without posing a great impact in the efficiency of the CSP performance. 
The recent introduction of 2μm-particle size CSPs and the instrumental improvements have led 
to the emergence of ultrahigh performance supercritical fluid based chromatography 
(UHPSFC) that merges the advantages of SFC and ultrahigh performance liquid 
chromatography technology, scarcely investigated for chiral analysis [11–13]. Furthermore, 
the addition of tandem mass spectrometry (MS/MS) detectors offers high sensitivity and 
selectivity, strongly needed for environmental analysis. Traditionally though, methods capable 
of enantiomeric separations have used ultraviolet detectors with non-volatile buffers or normal 
phase solvents incompatible with MS detectors. However, this trend is changing and more 
analytical methods using compatible-MS mobile phases are emerging [5,10,14,15]. 
The aim of this study was to develop a fast, selective and sensitive enantioselective method for 
the simultaneous analysis of 23 veterinary and human cPACs, belonging to 7 therapeutic 
groups (anthelmintic, antibacterial, antifungal, antihistamine, anti-inflammatory, cytostatic, 
and gastrointestinal drugs), in environmental samples (influent and effluent wastewater 
samples) using the novel approach of UHPSFC-MS/MS. In addition, the enantioselectivity of 
two modified polysaccharide-based CSPs with 2.5 μm particle size, an amylose tris-3,5-
dimethylphenylcarbamate (AMY) and a cellulose tris-(3-chloro-4-methylphenylcarbamate 
(CEL) column, was compared. The influence of mobile phase composition on the resolution of 
the enantiomers was also studied. 
 
2. Experimental 
2.1 Chemicals and reagents 
Table 1 shows the structures of cPACs. A set of 23 structurally different cPACs, covering 
acidic and basic compounds, was used as a model for the verification of chiral recognition with 
two modified polysaccharide-based CSPs. Selection of the cPACs was based on their high 
human and veterinary use worldwide and frequency of detection in the aquatic environment, 
possibility of chiral inversion during biological processes and commercial availability as 
racemic mixtures. Moreover, some chiral metabolites have also been selected. Please note that 
S-(+)-O-desmethylnaproxen is sold in its enantiomerically pure form. 
HPLC-grade acetonitrile (≥99.9%), methanol (≥99.9%) and isopropanol (≥99.9%), ammonium 
acetate (≥99.0%), ammonium hydroxide solution (28-30% NH3 basis), and formic acid 
(≥96.0%) were supplied by Sigma-Aldrich. R/S(±)-Aminorex, R/S(±)-carboxyibuprofen 
(mixture of diastereomers), R/S(±)-carprofen, S-(+)-O-desmethylnaproxen, R/S(±)-fenoprofen 
calcium salt hydrate, R/S(±)-2-hydroxyibuprofen, R/S(±)-ibuprofen, R/S(±)-ifosfamide, 
R/S(±)-imazalil (as sulphate), R/S(±)-indoprofen, R/S(±)-ketoprofen, R/S(±)-omeprazole, 
R/S(±)-ofloxacin, R/S(±)-2-phenylpropionic acid, R/S(±)-praziquantel, R/S(±)-tetramisole 
hydrochloride, S-(-)-tetramisole hydrochloride (known as levamisole), S-(-)-ofloxacin (known 
as levofloxacin) and1R,2R-(-)-chloramphenicol were purchased from Sigma-Aldrich 
(Gillingham, UK). R/S(±)-3-N-dechloroethylifosfamide, R/S(±)-dihydroketoprofen (mixture 
of diastereomers), R/S(±)-naproxen and S-(+)-naproxen were obtained from Toronto Research 
Chemicals Inc. (Ontario, Canada). R/S(±)-Fexofenadine hydrochloride, R/S(±)-cetirizine 
dihydrochloride and 1S,2S-(+)-chloramphenicol were supplied by LGC Standards 
(Teddington,UK). R/S(±)-Flurbiprofen and S-(+)-ibuprofen were purchased from Fisher. 
Surrogate/internal standards (IS): R/S(±)-ibuprofen-d3, R/S(±)-ifosfamide-d4, R/S(±)-
ketoprofen-d3, R/S(±)-naproxen-d3, R/S(±)-praziquantel-(cyclohexyl-d11) and R/S(±)-
tetramisole-d5 hydrochloride were purchased from LGC Standards (Teddington, UK) and 
Sigma-Aldrich (Gillingham, UK). 
All standards were of high purity grade. Stock solutions of each compound (1mg mL-1) were 
prepared in methanol and stored at -16°C. Working solutions were prepared by diluting stock 
solution in methanol and stored at -16°C. All glassware was deactivated with 
dimethylchlorosilane (5% DMDCS in toluene, Sigma-Aldrich) [16]. Oasis HLB (6cc, 200 mg, 
30 µm) and MAX (6cc, 200 mg, 30 µm) cartridges were bought from Waters (Milford, MA, 
USA). 
 
2.2 Sample collection, preparation and solid-phase extraction 
24-h composite influent and effluent wastewater samples were collected from a wastewater 
treatment plant in Western Europe in June 2015. In addition, 24-h composite influent and 
effluent wastewater samples from a wastewater treatment in Northern Europe were collected 
during 5 consecutive days in August 2015. All samples were collected in high density 
polyethylene sample bottles (Fisher, UK). Samples were frozen (-20ºC) immediately after 
collection and stored until analysis. 
 
2.3 Solid-phase extraction 
Solid-phase extraction (SPE) was used according to previously published protocols [10]. Some 
variations to the method were introduced. Briefly, Oasis HLB-MAX cartridges were set up in 
tandem and conditioned with 4 mL of methanol and equilibrated with 2 mL of deionized water 
at pH 7.5. Samples (50 mL of influent and effluent wastewater were spiked with a mixed 
solution of deuterated ISs (1 µg L-1). Samples were filtered and percolated through the 
cartridges at a flow rate of 6 mL min-1. SPE cartridges were washed individually: Oasis HLB 
with 2 mL water and Oasis MAX with 2 mL of 5% ammonium hydroxide; dried and connected 
in series afterwards. Analytes were eluted with four aliquots of 1mL methanol at a flow rate of 
1mL min-1, and additionally 2 aliquots of 1 mL methanol (2% formic acid) were passed through 
Oasis MAX cartridges. Eluates were combined, evaporated to dryness (40ºC) under a gentle 
stream of nitrogen, reconstituted with 0.5 mL of methanol and centrifugated at 21100 x g for 
10 min. A 5 μL of the sample was injected into the UHPSFC instrument. A flow chart of the 
SPE method can be found in Fig. 1. 
 
2.4 UHPSFC-MS/MS 
An UHPSFC instrument from Waters (Milford, MA, USA) equipped with an ACQUITY UPC2 
column manager, and ACQUITY UPC2 convergence manager (for automatic back pressure 
regulation), an ACQUITY UPC2 sample manager, an ACQUITY UPC2 binary solvent pump, 
and a Waters 515 compensation pump for post-column addition of a make-up flow, was used 
for this study. 
Separation was carried out using a modified polysaccharide amylose tris-3,5-
dimethylphenylcarbamate column (AMY, ACQUITY UPC2 Trefoil) and a cellulose tris-(3-
chloro-4-methylphenylcarbamate column (CEL, ACQUITY UPC2 Trefoil), both with the same 
dimensions (150 x 2.1 mm, i.d. 2.5 µm) (Waters, UK) (Fig. S1 in Supplementary Material). 
Column temperature was held at 30ºC and the flow-rate of the mobile phase was 1.5 mL min-
1. The active back pressure regulator was set at 1800 psi. The post-column flow was mixed 
with the make-up flow, containing methanol and 0.1% formic acid in positive ionization mode 
and methanol with 0.2% ammonium hydroxide in negative ionization mode, pumped at 0.3 mL 
min-1. Sample manager was kept at 15ºC. The screening step in positive and negative ionization 
mode was performed in a gradient elution programme in the following conditions: 0 min – 95 
% CO2, 1 min – 95 % CO2, 6 min – 40 % CO2, 8.5 min – 40% CO2, 8.7 min – 95 % CO2, 10 
min – 95% CO2. For AMY and CEL CSPs the optimized chromatographic conditions are as 
follow: separation was carried out using solvent A (CO2) and solvent B 
(methanol/acetonitrile/isopropanol, 1:1:1, v/v with 10mM ammonium acetate and 0.1% 
ammonium hydroxide) under a gradient program (0 min – 85 % A, 1 min – 85 % A, 5 min – 
40 % A, 7.5 min – 40% A, 7.8 min – 85 % A, 9 min – 85% A) in positive ionization mode. For 
cPACs detected in negative ionization mode the final optimized chromatographic conditions 
using AMY are as follow: gradient elution programme using solvent A (CO2) and solvent B 
(methanol with 0.1% ammonium hydroxide) (0 min –95% A, 3.5 min – 95% A, 10 min – 40% 
A, 13.5 min – 40% A, 13.8 min – 95% A, 16 min – 95% A). A flow chart is shown in Fig. 1. 
A volume of 5 µL was injected into the system. 
MS analyses were performed with a triple quadrupole mass spectrometer (Quattro Premier XE 
Mass Spectrometer, Waters Corp, Milford USA), equipped with an electrospray ionization 
source (ESI). Analyses were done in positive and negative modes. Ionization of analytes was 
carried out using the following settings: MS capillary voltage = 3 kV (ESI+) and 1.7 kV (ESI-
), desolvation temperature = 400°C, cone gas flow = 100 L h-1 and desolvation gas flow = 550 
L h-1. Nitrogen was used as a nebulising and desolvation gas and argon was used as the collision 
gas. MassLynx 4.1 (Waters, UK) software was used to collect and analyse the obtained data. 
Mass spectrometry analyses were performed in multiple reaction monitoring (MRM) mode. 
For each compound, two MRM transitions were monitored, except for O-desmethylnaproxen, 
dihydroketoprofen, flurbiprofen, 2-hydroxyibuprofen, ibuprofen, ibuprofen-d3, naproxen-d3, 
and 2-phenylpropionic acid for which only one MRM transition was chosen due to poor 
fragmentation. Details of the optimal TQD-MS conditions for each compound are summarized 
in Supplementary Material (Table S1). 
 
2.5 Method validation 
The performance of the analytical method was assessed with respect to linearity and range, 
precision, accuracy and sensitivity. 
To assess linearity and range of the analytical method, calibration curves of the target 
compounds were constructed at different concentrations, in the range of 0.005 to 1000 µg L-1 
for positive ionization mode and up to 8000 µg L-1 for negative ionization mode (after 
extraction) for each racemic mixture, injected in triplicate and prepared in stock standard 
solvent. The IS method was used for quantification. 
Precision was evaluated as the relative standard deviation (RSD) of replicate measurements. 
Instrumental intra- and inter- day precisions were determined through triplicate injections of 
standard solutions covering five concentrations: 0.5, and covering four concentrations: 2.5, 25, 
50 and 250 μg L-1 for each enantiomer with AMY CSP, on the same day for intra-day precision 
and on different days for inter-day precision. Method intra-day precision was estimated by 
recovery experiments in triplicate in influent and effluent wastewater fortified at three 
concentration levels (0.125, 2.5 and 5 μg L-1 in wastewaters for each enantiomer). 
Method accuracy (expressed as recovery percentage) was estimated from recovery experiments 
at three different concentration levels in spiked influent and effluent wastewater. Absolute 
recoveries were calculated as the ratio of the peak areas of spiked samples before extraction 
(the peak area of analyte in unspiked sample extract was subtracted) to those of a standard 
solution at the same concentrations level after extraction and concentration. Relative recoveries 
were calculated by comparing cPACs concentrations of spiked samples before extraction (the 
concentration in unspiked samples was subtracted) with cPACs concentrations in standard 
solutions prepared at the initial concentration level. 
Matrix effects were evaluated by the comparison of the peak areas of spiked wastewater 
extracts (Aspiked extract), to which the peak areas corresponding to the native analytes present in 
the sample were subtracted (Aunspiked), with the peak areas in the mobile phase spiked with 
target analytes (Amobile phase) at the same concentration level. 
𝑀𝑎𝑡𝑟𝑖𝑥 𝑒𝑓𝑓𝑒𝑐𝑡 (%) = 100 −
(𝐴𝑠𝑝𝑖𝑘𝑒𝑑 𝑒𝑥𝑡𝑟𝑎𝑐𝑡 − 𝐴𝑢𝑛𝑠𝑝𝑖𝑘𝑒𝑑)x100
𝐴𝑚𝑜𝑏𝑖𝑙𝑒 𝑝ℎ𝑎𝑠𝑒
 
Quantification was performed by the internal standard approach. Selection of ISs for those 
compounds for which deuterated or C13 analogues were not available commercially or in our 
laboratory was based on structural similarity, degree and type of matrix effects and elution time 
to account for possible signal suppression/enhancement, in those cases their analysis can only 
be considered semi-quantitative. 
Instrumental detection limits (IDL) and instrumental quantification limits (IQL) were 
calculated using signal-to-noise approach in standards prepared in mobile phase as the 
concentrations of each compound corresponding to signal-to-noise ratio of 3:1 and 10:1, 
respectively. Method detection limits (MDL) and method quantification limits (MQL) for 
wastewater were calculated as previously described in [10]. MDL and MQL were estimated 
from IDL and IQL, respectively, after taking into account recovery factor of each compound 
in each type of matrix and the concentration factor. 
 
2.6 Evaluation of the chromatographic system 
Chromatographic parameters, retention factor (k’), selectivity factor (α) and resolution (RS) 
were calculated to evaluate the retention, enantioselectivity and separation power, respectively 
(Supplementary Material Tables S2-S3): 
The enantiomeric fraction (EF) was calculated with both absolute and relative (normalised with 








where E1 and E2 are the peak areas (or concentrations) of the first and the second eluting 
enantiomer, respectively and (+) and (-) enantiomers if the elution order is known. EF equals 
1 or 0 in the case of single enantiomer form and 0.5 in the case of racemate. 
 
3. Results and discussion 
3.1 Screening of factors influencing enantioseparations in UHPSFC-MS/MS 
The nature of the CSP and the composition of the mobile phase are the factors that have the 
highest impact on chiral recognition. The screening strategy consisted on diverse experimental 
trials to achieve the best conditions to resolve the highest number of cPACs simultaneously. 
 
3.1.1. Nature of CSP  
Two modified coated polysaccharide-based CSPs with an amylose and cellulose base were 
thoroughly studied in terms of efficiency, retention and resolution of enantiomers.  
The mechanism of chiral discrimination of the polysaccharide CS involves a combination of 
attractive forces, such as hydrogen bonding between the ester and carbamate moieties of the 
CS and the corresponding functional groups of the enantiomers. Moreover, hydrophobic, 
dipole-dipole and π-π interactions and the geometric configuration of the CSP and the cPACs 
play an important role in chiral recognition [17]. 
CEL CSP exhibited, under tested conditions, optimal selectivity for the following pairs of 
enantiomers: aminorex, chloramphenicol (1R,2R and 1S,2S), 3-N-dechloroethylifosfamide, 
omeprazole, praziquantel and tetramisole (Fig. S2). In the case of ifosfamide, imazalil and 
ofloxacin their chiral resolution was dependent on the mobile phase composition (section 
3.1.2). None of the anti-inflammatory drugs were resolved using this CSP. What this group of 
cPACs have in common with the rest of non-resolved compounds (cetirizine and fexofenadine) 
is the presence of a carboxylic group in their structure (Table 1) (except ofloxacin). As stated 
in previous studies, the substituents on the phenyl moiety of the cellulose phenylcarbamate 
derivatives greatly affect chiral discrimination [17]. The presence of an electron withdrawing 
substituents (chloride group in position 3) affects the electron density of the CS, also increasing 
the acidity of the NH proton of the carbamate group [18]. 
In contrast to CEL CSP, AMY CSP exhibited an optimal selectivity for the two pairs of 
enantiomers of ifosfamide and its metabolite, while the resolution of the rest of cPACs 
(aminorex, carprofen, chloramphenicol, fenoprofen, flurbiprofen, 2-hydroxyibuprofen, 
ibuprofen, naproxen, omeprazole, praziquantel and tetramisole) were dependent on the mobile 
phase composition (section 3.1.2) (Fig. S3). 
As reported previously, amylose benzoates showed lower enantiomer recognition ability than 
cellulose benzoates, due to the lower conformational stability of the amylose derivatives [18]. 
Moreover, the presence of an electron-withdrawing group and an electron-donating group 
attached to the phenylcarbamate group in CEL CSP, in contrast to two electron-donating 
groups (alkyl groups in position 3 and 5) in AMY CSP would increase the enantiomer resolving 
ability of the former CSP. However, in this study it was observed that by further optimization 
of the mobile phase composition the success rate was higher with the AMY CSP for the target 
cPACs. 
 
3.1.2. Mobile phase optimization 
A mobile phase composed of CO2 provides normal-phase-like selectivity, so when polar 
compounds, such as cPACs are involved, it is necessary to add co-solvents and additives to 
increase the polarity of the mobile phase in order to elute all analytes and reduce analysis time. 
The content and nature of the organic modifier (co-solvent) can critically modulate chiral 
recognition as well as retention. According to literature [19] the presence of alcohols in the 
mobile phase yielded better resolutions with polysaccharide-based CSPs. In this study 
enantioseparations under CO2-based mobile phases modified with methanol, 2-propanol (both 
hydrogen bond donor/acceptor solvents) and acetonitrile (hydrogen bond acceptor/dipole 
solvent) and their mixtures were studied. As the concentration of the co-solvent is increased 
the polarity of the mobile phase increases resulting in reduced retention times. Co-solvent 
mixtures containing higher percentages of methanol resulted in lower retention times than 
when isopropanol or acetonitrile were the main components. 
For CEL CSP, the co-solvent mixtures gave the same success rate as when only single co-
solvents were used (Fig. S2). Regarding AMY CSP, resolution of most of the target analytes 
needed an optimization of the co-solvent composition. Fig. S3 shows that using ternary 
mixtures the number of successful enantioseparations increased in comparison to single co-
solvents alone. For example, a fraction of acetonitrile in the mobile phase was essential for the 
successful enantioseparation of omeprazole. Most of the cPACs eluted in 3.5 and 5 minutes, 
when the co-solvent content represented the 35-60% of the mobile phase. 
As in other chromatographic techniques, small quantities of additives can be used to improve 
peak shapes and/or resolution of the separation. They can modify the stationary phase surface 
or act as ion pairs changing selectivity of the target compounds. By combining different 
additives and their ratio, enantioseparations can be optimized, although not always in a 
predictable way [20]. Usually, for basic racemates a basic additive, such as diethylamine, 
ammonia or ammonium hydroxide may be necessary to mask acidic sites on the CSP surface 
and to suppress the ionization of the basic analytes, thus increasing their interaction with 
hydrophobic moieties part of the CSP [20]. In the case of acidic racemates an acidic additive 
(acetic, formic or trifluoroacetic acid) is recommended. In this study, additives must be 
compatible with MS detectors; therefore the addition of a salt (ammonium acetate), an acid 
(formic acid), a base (ammonium hydroxide) and their combination was investigated. No 
significant effects on tR and Rs were observed when the ammonium acetate content was 
increased from 10 mM to 20 mM (Fig. S3). However, the presence of ammonium acetate in 
the mobile phase was decisive for the chiral recognition of tetramisole in AMY CSP. 
Due to the “acidic” nature of CO2, it was expected that the use of formic acid would not 
favourably alter enantiomer selectivity compared with the addition of ammonium hydroxyde. 
When additives were present in the mobile phase Rs of chloramphenicol, 3-N-
dechloroethylifosfamide, flurbiprofen, 2-hydroxyibuprofen, ifosfamide, omeprazole, 
praziquantel and tetramisole increased (Fig. S3). However the addition of formic acid caused 
the loss of Rs of aminorex unlike when ammonium hydroxyde was used. After the benefits of 
adding ammonium hydroxide to the mobile phase were realized, an increase of its 
concentration (from 0.1% to 0.25%) was investigated. However, an increase of base 
concentration negatively altered the enantiomer selectivity (Fig. S3) and led to lower signal-
to-noise ratios. 
In summary, a mobile phase consisting of CO2 as primary eluent and a ternary co-solvent 
mixture formed by methanol/isopropanol/acetonitrile (1:1:1, v/v/v) with 10 mM ammonium 
acetate and 0.1% ammonium hydroxide yielded the best simultaneous resolution for the highest 
number of compounds on AMY and CEL CSP in the positive ionization mode (Fig. 2A and 
2B). The selection of the same chromatographic conditions for both CSPs would allow running 
them in parallel, simplifying the process, reducing running times and as a consequence 
increasing the economic benefits. The same screening approach was performed for each CSP 
also in the negative mode. Unlike AMY CSP, CEL CSP did not show any enantiomer 
selectivity for cPACs monitored in negative mode and therefore no further method 
development was undertaken for this CSP. On the other hand, AMY CSP and a mobile phase 
composed by CO2 as primary eluent and methanol modified with 0.2% ammonium hydroxide, 
combined with a softer gradient (section 2.4), resulted in excellent chiral recognition for: 
carprofen (Rs=2.3), chloramphenicol (Rs=1.2), flurbiprofen (Rs=2.3), 2-hydroxyibuprofen 
(Rs=1.8), ibuprofen (Rs=0.7) and naproxen (Rs=1.5) (Fig. 2C). The verification of the elution 
order of studied cPACs, under the final conditions, was possible only in the case of 
chloramphenicol, ibuprofen, naproxen, ofloxacin and tetramisole as standards of single 
enantiomers were commercially available for only these compounds. 
For the following cPACs: carboxyibuprofen, cetirizine, dihydroketoprofen, fexofenadine, 
indoprofen, ketoprofen, mandelic acid and 2-phenylpropionic acid no enantiomer selectivity 
was observed under any of the chromatographic conditions studied with both CSPs in both 
ionization modes and therefore AMY and CEL CSPs are not considered appropriate for those 
cPACs. 
 
3.3 Method validation 
The analytical performance of the proposed method was evaluated in terms of linearity, limits 
of detection and quantification, precision and accuracy. Method validation data for cPACs is 
presented in Tables 2-3 and Tables S4-S9 (Supplementary Material). 
Linearity was studied at 15 different concentration levels (ranging from 0.005 to 1000 µg L-1 
for positive ionization mode and up to 8000 µg L-1 for negative ionization mode, for each 
racemic mixture). Good linearity of the analytical response was observed with global mean 
correlation coefficients equal or higher than 0.995 (Tables S4 and S5). 
Precision was within the acceptable limits (≤20%). Both instrumental intra-day and inter-day 
precision (assessed over three days across the range of concentrations) were in general lower 
than 10% and 15%, respectively (Tables S4 and S5). The overall method intra-day precision, 
estimated from recovery experiments in influent and effluent wastewater at three concentration 
levels was on average below 15% (Supplementary Material Tables S6-S9). 
Method accuracy (expressed as recovery percentage) was evaluated by recovery experiments 
of target compounds in influent and effluent wastewater samples, spiked in triplicate at three 
fortification levels (0.125, 2.5 and 5 μg L-1 for each enantiomer) (Supplementary Material 
Tables S6-S9). In general average recoveries were satisfactory at three fortification levels 
which were typically >70% (Fig. 3 and 4) for both CSPs. Low recoveries were obtained for 3-
N-dechloroethylifosfamide, ofloxacin and omeprazole. As it has been stated in previous studies 
[16,21–23] retention of PACs in SPE sorbents is strongly affected by the pH of the eluent, 
therefore the chosen conditions may not be the optimal to recover these cPACs. In fact, this is 
one of the limitations of multi-residue analytical methods, where a compromise on the final 
analytical conditions has to be reached to achieve the best conditions for the highest number of 
cPACs. As can be seen in Tables S6-S9, recoveries at low, medium or high spike levels were 
not provided for some cPACs in the non-spiked influent (cetirizine and fexofenadine) and 
effluent wastewater samples (cetirizine, fexofenadine, 2-hydroxyibuprofen, ketoprofen and 
naproxen) because they were present at high concentration levels in the non-spiked wastewater 
samples or because the spike concentration level was close or lower than their IDL. 
The presence of interfering substances can lead to inaccurate results due to matrix effects. 
Several strategies to reduce this detrimental effects have been reported in LC-MS/MS (e.g. 
purification of the sample prior to analysis and/or the use of suitable calibration approaches 
[24,25], but just a few studies concerning determination of matrix effects in SFC-MS/MS have 
been reported so far [26]. Matrix effects were evaluated by comparison of the signal of each 
compound spiked in matrix after SPE with the signal of the compound in mobile phase. Results 
are displayed in Fig. 5. Signal suppression was observed for most of the enantiomers. Average 
matrix effects ranged from -89 % (2-hydroxyibuprofen E2) to 28 % (carprofen E1) in influent 
wastewater and from -48 % (2-hydroxyibuprofen E1) to 14 % (flurbiprofen E1) in effluent 
wastewater with the AMY CSP. Regarding CEL CSP, matrix effects ranged from -89% 
(omeprazole E1) to 96% (R-(-)-naproxen) in influent wastewater and from -40% (praziquantel 
E1) to 4% (N-dechloroethylifosfamide E1) in effluent wastewater. As expected matrix effects 
were more pronounced with an increase of the complexity of the matrix. Differences in matrix 
effects between enantiomers of the same compound were also observed, especially when AMY 
CSP was involved. The results showed that the signal of the second eluted enantiomer was 
more suppressed than the first eluted enantiomer (e.g.: aminorex, carprofen, 3-N-
dechloroethylifosfamide and fenoprofen) in AMY CSP, independently of the matrix. Whereas, 
the same trend was also observed for 3-N-dechloroethylifosfamide in CEL CSP, the pair of 
enantiomers of indoprofen showed the reversed pattern, with the first eluted enantiomer 
showing higher suppression than the second one. 
The instrumental limits of detection and quantification were estimated using the signal-to-noise 
ratio approach. The results are summarized in Table 2 and 3 for all the compounds studied. The 
results indicated a wide variety of MDLs. Compounds ionized in negative mode showing the 
highest MDLs. No significant differences were found between the results obtained for influent 
and effluent wastewater samples. The most sensitive cPACs included: aminorex, 3-N-
dechloroethylifosfamide, fexofenadine (with CEL CSP), ifosfamide, imazalil, indoprofen, 
praziquantel and tetramisole with MDLs of less than 10 ng L-1 with both CSPs. This group of 
cPACs contains amino groups (in the rings) and also chlorine, sulphur or fluorine atoms in their 
chemical structure. For the rest of cPACs their MDLs depended on the CSP used. Regarding 
CEL CSP, ketoprofen, ofloxacin and omeprazole had a MDL < 100 ng L-1 and naproxen < 300 
ng L-1. In the case of AMY CSP: fenoprofen, flurbiprofen, ketoprofen and ofloxacin were in 
the range between 150 and 500 ng L-1 and other cPACs had MDLs > 500 ng L-1. The majority 
of compounds with high MDLs corresponded to the anti-inflammatory group which were 
monitored in negative mode and had hydroxyl or carboxylic groups present in their chemical 
structure. 
 
3.4 Application to environmental samples 
To ascertain its applicability, the validated UHPSFC-MS/MS method was applied to 
wastewater samples. Ten 24-h composite influent and effluent wastewater samples, collected 
during 5 consecutive days from a wastewater treatment plant situated in Northern Europe and 
two additional 24-h composite influent and effluent wastewater samples from Central Europe 
were analyzed. 
The results indicated low concentrations of targeted analytes in samples from Northern Europe, 
however two compounds were quantified (fexofenadine and ketoprofen). Fexofenadine was 
present at quantitative concentration levels in all samples. Concentrations of fexofenadine 
ranged from 0.66 to 0.95 µg L-1 and from 0.60 to 0.77 µg L-1 in influent and effluent wastewater 
samples, respectively. Ketoprofen was detected in all influent wastewater samples (<MQL-
1.09 µg L-1) but only in two effluent wastewater samples (<MDL-0.68 µg L-1). Whereas the 
mean removal rate of fexofenadine was lower than 10%, the mean removal rate of ketoprofen 
was>80%. 
In contrast to samples from Northern Europe, wastewater samples from Western Europe 
contained much higher concentrations of cPACs and frequency of detection (Table 4). 
Out of the 22 target compounds monitored, 10 were detected in influent wastewater samples 
(aminorex, carboxyibuprofen, dihydroketoprofen, fexofenadine, 2-hydroxyibuprofen, 
ibuprofen, imazalil, naproxen, ofloxacin and tetramisole) and 3 in effluent wastewater samples 
(fexofenadine, naproxen and tetramisole). 
The highest concentration levels of cPACs in influent wastewater samples corresponded to the 
anti-inflammatory cPACs and their metabolites. Only the S-enantiomer of ibuprofen was 
present with a concentration level that reached up to 5.24 μg L-1. Although ibuprofen is 
marketed as a racemic mixture, an excess of S-(+)-ibuprofen is excreted in the urine, due to an 
extensive chiral inversion of the inactive R-(-)-ibuprofen during metabolism. S-(+)-ibuprofen 
was found to be predominant in both influent and effluent wastewater, which is in accordance 
with published results [27–29]. Ibuprofen metabolites were detected at higher concentration 
levels than the parent compound. R/S(±)-carboxyibuprofen and 2-hydroxyibuprofen E2 
reached 11.1 and 13.3 μg L-1, respectively, whereas the concentration of the first eluted 
enantiomer of 2-hydroxyibuprofen reached 2.81 μg L-1 in influent wastewaters. The EF of 2-
hydroxyibuprofen was therefore 0.2. These concentration levels were higher than those 
reported previously [10]. Unlike ibuprofen, naproxen is marketed as the enantiomerically pure 
S-enantiomer, due to the well-known negative effects of R-naproxen. S-(+)-naproxen was 
detected in influent and effluent wastewater at concentration levels of 4.75 and 0.95 μg L-1, 
respectively, what represented a removal rate up to 83 %. The EF of naproxen (1.0) did not 
change during wastewater treatment. Although the concentration of R/S(±)-ketoprofen was 
<MQL, its main metabolite was present in influent wastewater at 0.42 μg L-1. 
Tetramisole enantiomers were detected at 0.05 (R-enantiomer) and 0.03 (S-enantiomer) μg L-
1 in influent wastewater and at 0.09 (R-enantiomer) and 0.05 (S-enantiomer) μg L-1 in effluent 
wastewater. The EF remained unaltered during wastewater treatment, with an excess of the R-
enantiomer. Information regarding concentration levels of this veterinary cPAC in the 
environment remains scarce. Concentration levels of tetramisole enantiomers are similar or 
higher than those reported previously in effluent wastewaters from UK [10]. Due to the 
anthelmintic activity of tetramisole residing in its S-enantiomer (levamisole), this cPAC is 
marketed as enantiomerically pure S-enantiomer. Therefore the presence of both enantiomers 
in influent wastewater suggests that chiral inversion took place during human and animal 
metabolism. Is is also possible that the racemic mixture of tetramisole was used as an adulterant 
in illicit cocaine samples [30,31]. The metabolites of tetramisole were also quantified. 
Aminorex E1 was present at 0.02 μg L-1 and E2 was quantified at 0.01 μg L-1 in influent 
wastewater. 
R/S(±)-fexofenadine, imazalil E2 and S-(-)-ofloxacin also detected in wastewater samples. 
R/S(±)-fexofenadine was detected in both matrices at concentration levels similar to those 
reported for the samples from Northern Europe. In addition, no removal of this compound was 
observed, which indicates that fexofenadine is recalcitrant. In the case of the antifungal cPAC 
imazalil, there was an excess of the second eluted enantiomer in influent wastewater samples, 
with total concentration of 0.028 μg L-1, whereas its concentration in effluent wastewater was 
below MDL. Imazalil is employed as a racemic mixture and the general population can be 
exposed to it through contaminated food. A previous study has shown that the binding of 
imazalil to human proteins, specifically human serum albumin, is enantioselective [32], what 
could suggest that imazalil is excreted with an excess of one enantiomer or that chiral inversion 
took place, but this effect has been scarcely studied so there is not enough information available 
regarding this effect. Moreover, recent published data showed that the S-(-)-enantiomer 
degrades quicker than the R-(+)-enantiomer [33,34], what could explain the presence of only 
one enantiomer in influent wastewater samples. 
Finally, S-(-)-ofloxacin (levofloxacin) was found to be readily removed during wastewater 
treatment. It was present in influent wastewater at concentration levels of 0.539 μg L-1. 
Ofloxacin is a potent quinolone antibacterial agent marketed as enantiomerically pure S-(-)-
ofloxacin since 1995, although it can be marketed as the racemic mixture too. It has been 
reported that the S-(-)-enantiomer has antibacterial activity up to 2 orders of magnitude greater 
than that of the R-(+)-enantiomer due to the greater binding potency of the S(-)-enantiomer to 
the enzyme-DNA complex [35]. S-(-)-ofloxacin is excreted from the body unchanged and up 
to date no chiral inversion has been reported in the environment. 
 
4. Conclusions 
Two novel enantioselective analytical methods, based on SPE before analysis by UHPSFC-
MS/MS, were developed for the simultaneous analysis of several cPACs in wastewater 
samples.  Baseline resolution (13 cPACs) and partial resolution (2 cPACs) for the pair of 
enantiomers of 23 cPACs belonging to 7 different therapeutic groups was achieved in less than 
10 min.  
Enantioseparation was achieved with two modified polysaccharide-based CSPs which 
exhibited complementary separation properties. The nature and concentration of the co-solvent 
was the most important parameter to achieve successful enantioseparation of the target 
compounds. The validation data confirmed satisfactory analytical performance in terms of 
mean recoveries, linearity, accuracy, precision, sensitivity and selectivity. Although 
pronounced matrix effects were encountered for some cPACs in these complex environmental 
samples, the internal standard approach proved to be a practical option. If increased sample 
throughput and short analyses are required, it is of high significance to use a plausible approach, 
such as an effective sample preparation, in order to avoid inaccurate quantification in real 
samples due to matrix effects. 
Under the optimized conditions, the developed methods were successfully applied to the 
analysis of cPACs in real wastewater samples. Out of 22 target compounds monitored, 11 
(aminorex, carboxyibuprofen, dihydroketoprofen, fexofenadine, 2-hydroxyibuprofen, 
ibuprofen, imazalil, ketoprofen, naproxen, ofloxacin and tetramisole) were detected in influent 
and effluent wastewaters and not always as racemic mixtures. Tracing chemically diverse 
cPACs at enantiomeric level in environmental matrices is vital for a proper understanding of 
the possible environmental risks posed by these compounds. This study demonstrates a suitable 
alternative and environmentally friendly method to existing complex and time consuming 
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4 x 1 mL
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Elution 2






• Filtration through GF/F filters (0.7 µm)
• 50 mL of wastewater spiked with 50 ng of a mixture of ISs
• SPE (Oasis HLB-MAX in tandem)
Conditioning and
equilibration
4 mL methanol + 2 mL 







• Evaporation of combined eluates to dryness (40 oC, N2)
• Reconstitution in 0.5 mL of methanol
• Centrifugation at 21100 x g for 10 min.
Analysis by UHPSFC-MS/MS
• Mobile phase A: CO2
• Mobile phase B: methanol containing 0.1% ammonium 
hydroxide
• Flow rate: 1.5 mL min-1
• Gradient: 0 min – 95% A, 3.5 min – 95% A, 10 min – 40% 
A, 13.5 min – 40% A, 13.8 min – 95% A, 16 min – 95% A
• Make-up flow: methanol modified with 0.2% ammonium 
hydroxide at 0.3 mL min-1
• Column temperature: 30 oC
• Backpressure: 1800 psi
• Sample manager: 15oC
• Injection volume 5 µL
• Mobile phase A: CO2
• Mobile phase B: methanol/acetonitrile/isopropanol (1:1:1,
v/v) containing 10 mM ammonium acetate and 0.1%
ammonium hydroxide
• Flow rate: 1.5 mL min-1
• Gradient: 0 min – 85% A, 1 min – 85% A, 5 min – 40% A,
7.5 min – 40% A, 7.8 min – 85% A, 9 min – 85% A
• Make-up flow: methanol modified with 0.1% formic acid
at 0.3 mL min-1
• Column temperature: 30 oC
• Backpressure: 1800 psi
• Sample manager: 15oC
• Injection volume 5 µL
Analysis in ESI + mode
AMY CSP
(150 x 2.1 mm, i.d. 2.5 µm)
CEL CSP
(150 x 2.1 mm, i.d. 2.5 µm)
AMY CSP
(150 x 2.1 mm, i.d. 2.5 µm)
Analysis in ESI - mode
 
Fig. 2. Chromatograms of cPACs in standard solution (250 ng/mL) in CEL (A) and AMY (B) 
in positive ionization mode and in AMY (C) in negative ionization mode 
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Fig. 3. Mean Absolute and relative recoveries (%) of cPACs in influent and effluent 








































Fig. 4. Mean Absolute and relative recoveries (%) of cPACs in influent and effluent 










































Fig. 5. Matrix effects (%) of cPACs in influent and effluent wastewater with AMY CSP (A) 







































































































































































































































































































































































































































































































































Amylose tris-(3,5-dimethylphenylcarbamate) (AMY) 
 
 
Cellulose tris-(3-chloro-4-methylphenylcarbamate) (CEL) 
Fig. S1. Structure of the AMY and CEL chiral selector 
  
 
Fig. S2. Effects of mobile phase composition on the enantioseparation of several cPACs in 
CEL (chromatographic conditions: mobile phase: CO2 (A’)/co-solvent (A-H) (B’); gradient: 0 
min – 95 % A’, 1 min – 95 % A’, 6 min – 40 % A’, 8.5 min – 40% A’, 8.7 min – 95 % A’, 10 
min – 95% A’;  flow: 1.5 mL/min; ABPR: 1800psi; make-up flow: methanol (0.1% formic 
acid) for positive ionization and methanol (0.2% ammonium hydroxide) for negative ionization 
at 0.3 mL min-1) 
  
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
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LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
Mix 200 ppb_CEL2_MEOH/ACN(1:1)+10mM Am.Acetate_Make up  MeOH+0.1%FA
Time




LCM150817_086 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
8.12e5
Mix 200 ppb_CEL2_MEOH/ACN(1:1)+0.1%FA_Make up MeOH+0.1%FA
Time




LCM150817_094 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
9.62e5
Mix 200 ppb_CEL2_IPA/ACN(1:1)+0.1%NH4OH_Make up  MeOH+0.1FA
Time




LCM150817_091 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
3.86e5
Mix 200 ppb_CEL2_MEOH_Make up MeOH+0.1%FA
Time




LCM150814_068 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
3.98e5
Mix 200 ppb_CEL2_MEOH+10mM Am.Acetate_Make up MeOH+0.1%FA
Time




LCM150814_076 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
4.44e5
Mix 200 ppb_CEL2_MEOH+0.1%NH4OH_Make up MeOH+0.1%FA
Time




LCM150814_070 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
9.37e5
Mix 200 ppb_CEL2_MEOH/IPA/ACN(1:1:1)+10mM Am.Acetate +0.1%NH4OH_Make up MeOH+0.1%FA
Time




LCM150817_084 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
4.03e5
Aminorex
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.2%NH4
Time




LCM150817_080 4: MRM of 2 Channels ES- 
320.8 > 151.8 (Chloramphenicol)
1.62e5
Mix 2 0 ppb_CEL2_MEOH/ACN(1:1)+10mM Am.Acetate_Make up  MeOH+0.2NH4
Time




LCM150817_088 4: MRM of 2 Channels ES- 
320.8 > 151.8 (Chloramphenicol)
1.55e5
Mix 200 ppb_CEL2_MEOH/ACN(1:1)+0.1%FA_Make up MeOH+0.2%NH4
Time




LCM150817_096 4: MRM of 2 Channels ES- 
320.8 > 151.8 (Chloramphenicol)
1.76e5
Mix 200 ppb_CEL2_IPA/ACN(1:1)+0.1%NH4OH_Make up  MeOH+0.2NH4
Time




LCM150817_089 4: MRM of 2 Channels ES- 
320.8 > 151.8 (Chloramphenicol)
1.04e5
Mix 200 ppb_CEL2_MEOH_Make up MeOH+0.2%NH4
Time




LCM150814_066 4: MRM of 2 Channels ES- 
320.8 > 151.8 (Chloramphenicol)
1.13e5
Mix 200 ppb_CEL2_MEOH+10mM Am.Acetate_Make up MeOH+0.2%NH4
Time




LCM150814_074 4: MRM of 2 Channels ES- 
320.8 > 151.8 (Chloramphenicol)
1.03e5
Mix 200 ppb_CEL2_MEOH+0.1%NH4OH_Make up MeOH+0.2%NH4
Time




LCM150814_072 4: MRM of 2 Channels ES- 
320.8 > 151.8 (Chloramphenicol)
1.38e5
Mix 200 ppb_CEL2_MEOH/IPA/ CN(1:1:1)+10mM Am.Acetate +0.1%NH4OH_Make up MeOH+0.2%NH4
Time




LCM150817_082 4: MRM of 2 Channels ES- 
320.8 > 151.8 (Chloramphenicol)
1.60e5
Chloram-
phenicolMix 200 ppb_CEL2_ E /ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 11: MRM of 2 Channels ES+ 
198.9 > 77.9 (N-Dechloroethyl cyclophosphamide)
9.47e5
Mix 200 ppb_CEL2_MEOH/ACN(1:1)+10mM Am.Acetate_Make up  MeOH+0.1%FA
Time




LCM150817_086 11: MRM of 2 Channels ES+ 
198.9 > 77.9 (N-Dechloroethyl cyclophosphamide)
1.09e6
Mix 200 ppb_CEL2_MEOH/ACN(1:1) .1 FA_Make up MeOH+0.1%FA
Time




LCM150817_094 11: MRM of 2 Channels ES+ 
198.9 > 77.9 (N-Dechloroethyl cyclophosphamide)
8.36e5
Mix 200 ppb_CEL2_IPA/ACN(1:1)+0.1%NH4OH_Make up  MeOH+0.1FA
Time




LCM150817_091 11: MRM of 2 Channels ES+ 
198.9 > 77.9 (N-Dechloroethyl cyclophosphamide)
2.74e5
Mix 200 pb_CEL2_MEOH_Make up MeOH+0.1%FA
Time




LCM150814_068 11: MRM of 2 Channels ES+ 
198.9 > 77.9 (N-Dechloroethyl cyclophosphamide)
2.91e5
Mix 200 ppb_CEL2_ EOH+10mM Am.Acetate_Make up MeOH+0.1%FA
Time




LCM150814_076 11: MRM of 2 Channels ES+ 
198.9 > 77.9 (N-Dechloroethyl cyclophosphamide)
2.97e5
Mix 200 ppb_CEL2_MEOH+0.1%NH4OH_Make up MeOH+0.1%FA
Time




LCM150814_070 11: MRM of 2 Channels ES+ 
198.9 > 77.9 (N-Dechloroethyl cyclophosphamide)
1.16e6
Mix 200 ppb_CEL2_MEOH/IPA/ACN(1:1:1)+10mM Am.Acetate +0.1%NH4OH_Make up MeOH+0.1%FA
Time




LCM150817_084 11: MRM of 2 Channels ES+ 
198.9 > 77.9 (N-Dechloroethyl cyclophosphamide)
3.85e5
3-N-Dechloro
thylifosfamideMix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 4: MRM of 4 Channels ES+ 
261 > 91.95 (Ifosfamide)
6.47e5
43Mix 2 0 ppb_CEL2_MEOH/ACN(1:1)+10mM Am.Acetate_Make up  MeOH+0.1%FA
Time




LCM150817_086 4: MRM of 4 Channels ES+ 
261 > 91.95 (Ifosfamide)
7.86e5
43Mix 200 ppb_CEL2_MEOH/ACN(1:1)+0.1%FA_Make up MeOH+0.1%FA
Time




LCM150817_094 4: MRM of 4 Channels ES+ 
261 > 91.95 (Ifosfamide)
7.14e5
43Mix 200 ppb_CEL2_IPA/ACN(1:1)+0.1%NH4OH_Make up  MeOH+ .1FA
Time




LCM150817_091 4: MRM of 4 Channels ES+ 
261 > 91.95 (Ifosfamide)
1.62e5
43Mix 200 ppb_CEL2_MEOH_Make up MeOH+0.1%FA
Time




LCM150814_068 4: MRM of 4 Channels ES+ 
261 > 91.95 (Ifosfamide)
1.36e5
43Mix 200 ppb_CEL2_MEOH+10mM Am.Acetate_Make up MeOH+0.1%FA
Time




LCM150814_076 4: MRM of 4 Channels ES+ 
261 > 91.95 (Ifosfamide)
1.68e5
43
Mix 200 ppb_CEL2_MEOH+0.1%NH4OH_Make up MeOH+0.1%FA
Time




LCM150814_070 4: MRM of 4 Channels ES+ 
261 > 91.95 (Ifosfamide)
4.47e5
43
Mix 200 ppb_CEL2_MEOH/IPA/ACN(1:1:1)+10mM Am.Acetate +0.1%NH4OH_Make up MeOH+0.1%FA
Time




LCM150817_084 4: MRM of 4 Channels ES+ 




Mix 200 ppb_CEL2_MEOH/ CN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 10: MRM of 2 Channels ES+ 
297 > 158.9 (Imazalil sulphate)
9.02e5
Mix 200 ppb_CEL2_MEOH/ACN(1:1)+10mM Am.Acetate_Make up  MeOH+0.1%FA
Time




LCM150817_086 10: MRM of 2 Channels ES+ 
297 > 158.9 (Imazalil sulphate)
6.19e5
Mix 2 0 ppb_CEL2_MEOH/ACN(1:1)+0.1%FA_Make up MeOH+0.1%FA
Time




LCM150817_094 10: MRM of 2 Channels ES+ 
297 > 158.9 (Imazalil sulphate)
9.80e5
Mix 2  ppb CEL2_IPA/ACN(1:1)+ .1%NH4OH_Make up  MeOH+0.1FA
Time




LCM150817_091 10: MRM of 2 Channels ES+ 
297 > 158.9 (Imazalil sulphate)
3.64e5
Mix 200 ppb_CEL2_MEOH_Make up MeOH+0.1%FA
Time




LCM150814_068 10: MRM of 2 Channels ES+ 
297 > 158.9 (Imazalil sulphate)
3.47e5
Mix 200 ppb_CEL2_MEOH+1 mM m.Acetate_Make up MeOH+0.1%FA
Time




LCM150814_076 10: MRM of 2 Channels ES+ 
297 > 158.9 (Imazalil sulphate)
4.00e5
Mix 200 ppb_CEL2_MEOH+0.1%NH4OH_Make up MeOH+0.1%FA
Time




LCM150814_070 10: MRM of 2 Channels ES+ 
297 > 158.9 (Imazalil sulphate)
6.74e5
ix 200 ppb_CEL2_MEOH/IPA/ACN(1:1:1)+10mM Am.Acetate +0.1%NH4OH_Make up MeOH+0.1%FA
Time




LCM150817_084 10: MRM of 2 Channels ES+ 






362.22 > 261.11 (Ofloxacin
1 9 4
i   / ( : )  . t t    .
Ti e
- . . 2. 3.00 4.00 5.00 6.00 7.00 8.00
%
1:  of 2 hannels + 
362.22 > 261.11 (Ofloxacin)
9.10e3
ix 200 ppb_ EL2_ E / (1:1)+0.1 F _ ake up e +0.1 F
Ti e




LC 150817_094 1: R  of 2 Channels ES+ 
362.22 > 261.11 (Ofloxacin)
1.75e4
i  0 I / ( : ) 0.    .
i
- . 0 . . . . . .
%
1:  f  l   
362.22 > 261.11 (Ofloxacin)
6.27 3
Mix 200 ppb_CEL2_MEOH_Make up MeOH+0.1%FA
Time




LCM150814_068 1: MRM of 2 Channels ES+ 
362.22 > 261.11 (Ofloxacin)
4.84e3
Mix 200 ppb_CEL2_MEOH+10mM Am.Acetate_Make up MeOH+0.1%FA
Time




LCM150814_076 1: MRM of 2 Channels ES+ 
362.22 > 261.11 (Ofloxacin)
3.19e3
Mix 20  ppb_CEL2_MEOH+0.1%NH4OH_Make up MeOH+0.1%FA
Time




LCM150814_070 : MRM of 2 Chan els ES+ 
TIC (Ofloxacin)
8.02e3
ix 200 ppb_ L2_ /I / (1:1:1)+10  . cetate 0.1 4 _ ake  e 0.1
Ti e




L 150817_084 1:  of 2 hannels + 
362.22 > 261.11 (Ofloxacin)
5.74e3
Ofloxacin
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 12: MRM of 3 Channels ES+ 
346.1 > 198.1 (Omeprazole)
1.12e6
Mix 200 ppb_CEL2_MEOH/ACN(1:1)+10mM Am.Acetate_Make up  MeOH+0.1%FA
Time




LCM150817_086 12: MRM of 3 Channels ES+ 
346.1 > 198.1 (Omeprazole)
8.79e5
Mix 200 ppb_CEL2_MEOH/ACN(1:1)+0.1%FA_Make up MeOH+0.1%FA
Time




LCM150817_094 12: MRM of 3 Channels ES+ 
346.1 > 198.1 (Omeprazole)
8.12e5
Mix 2 0 ppb_CEL2_IPA/ACN(1:1)+ .1%NH4OH_Make up  MeOH+0.1FA
Time




LCM150817_091 12: MRM of 3 Channels ES+ 
346.1 > 136.06 (Omeprazole)
2.08e5
Mix 200 ppb_CEL2_MEOH_Make up MeOH+0.1%FA
Time




LCM150814_068 12: MRM of 3 Channels ES+ 
346.1 > 136.06 (Omeprazole)
3.21e5
Mix 200 ppb_CEL2_MEOH+10mM Am.Acetate_Make up MeOH+0.1%FA
Time




LCM150814_076 12: MRM of 3 Channels ES+ 
346.1 > 136.06 (Omeprazole)
2.69e5
Mix 200 ppb_CEL2_MEOH+0.1%NH4OH_Make up MeOH+0.1%FA
Time




LCM150814_070 12: MRM of 3 Channels ES+ 
346.1 > 136.06 (Omeprazole)
5.80e5
Mix 200 ppb_CEL2_MEOH/IPA/ACN(1:1:1)+10mM Am.Acetate +0.1%NH4OH_Make up MeOH+0.1%FA
Time




LCM150817_084 12: MRM of 3 Channels ES+ 
346.1 > 136.06 (Omeprazole)
2.27e5
Omeprazole
Mix 200 ppb_CEL2_MEOH/ CN(1:1)_Make up MeOH+0.1%FA
Time




LCM 50817_078 15: MRM of 4 Channels ES+ 
313.1 > 83 (Praziquantrel)
1.91e5
Mix 200 ppb_CEL2_MEOH/ACN(1:1)+10mM Am.Acetate_Make up  MeOH+0.1%FA
Time




LCM150817_086 15: MRM of 4 Channels ES+ 
313.1 > 83 (Praziquantrel)
2.18e5
Mix 2 0 ppb_CEL2_MEOH/ACN(1:1)+0.1%FA_Make up MeOH+0.1%FA
Time




LCM 50817_094 15: MRM of 4 Channels ES+ 
313.1 > 83 (Praziquantrel)
2.01e5
Mix 200 ppb_CEL2_IPA/ACN(1:1)+0.1%NH4OH_Make up  MeOH+0.1FA
Time




LCM15 817_091 15: MRM of 4 Channels ES+ 
313.1 > 83 (Praziquantrel)
8.09e4
Mix 200 ppb_CEL2_MEOH_Make up MeOH+0.1%FA
Time




LCM 50814_068 15: MRM of 4 Channels ES+ 
313.1 > 83 (Praziquantrel)
9.43e4
Mix 200 ppb_CEL2_MEOH+10mM Am.Acetate_Make up MeOH+0.1%FA
Time




LCM150814_076 15: MRM of 4 Channels ES+ 
313.1 > 83 (Praziquantrel)
1.25e5
Mix 200 ppb_CEL2_MEOH+0.1%NH4OH_Make up MeOH+0.1%FA
Time




LCM15 814_070 15: MRM of 4 Channels ES+ 
313.1 > 83 (Praziquantrel)
2.82e5
Mix 200 ppb_CEL2_MEOH/IPA/ACN(1:1:1)+10mM Am.Ac tate +0.1%NH4OH_Make up MeOH+0.1%FA
Time




LCM 50817_084 15: MRM of 4 Channels ES+ 
313.1 > 83 (Praziquantrel)
1.01e5
Praziquantel
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 2: MRM of 4 Channels ES+ 
205 > 91 (Tetramisole HCl)
1.60e6
ix 200 ppb_CEL2_MEOH/ACN(1:1)+10mM Am.Acetate_Make up  MeOH+0.1%FA
Time




LCM150817_086 2: MRM of 4 Channels ES+ 
205 > 91 (Tetramisole HCl)
1.32e6
Mix 20  ppb_CEL2_MEOH/ACN(1:1)+0.1%FA_Make up MeOH+0.1%FA
Time




LCM1508 7_094 2: MRM of 4 Channels ES+ 
205 > 91 (Tetramisole HCl)
1.56e6
ix 20  ppb_CEL2_IPA/ACN(1:1)+0.1%NH4OH_Make up  MeOH+0.1FA
Time




LCM150817_091 2: MRM of 4 Channels ES+ 
205 > 91 (Tetramisole HCl)
9.16e5
Mix 200 ppb_CEL2_MEOH_Make up MeOH+0.1%FA
Time




LCM150814_068 2: MRM of 4 Channels ES+ 
205 > 91 (Tetramisole HCl)
7.70e5
Mix 200 ppb_CEL2_MEOH+10mM Am.Acetate_Make up MeOH+0.1%FA
Time




LCM150814_076 2: MRM of 4 Channels ES+ 
205 > 91 (Tetramisole HCl)
7.49e5
Mix 200 ppb_CEL2_MEOH+0.1%NH4OH_Make up MeOH+0.1%FA
Time




LCM150814_070 2: MRM of 4 Channels ES+ 
205 > 91 (Tetramisole HCl)
1.02e6
Mix 2 0 ppb_CEL2_ EOH/IPA/ACN(1:1:1)+10mM Am.Acetate +0.1%NH4OH_Make up MeOH+0.1%FA
Time




LCM150817_084 2: MRM of 4 Channels ES+ 










































































Methanol/acetonitrile (1:1, v/v) + 10mM ammonium acetate
Methanol/acetonitrile (1:1,v/v) + 0.1% formic acid
Isopropanol/acetonitrile (1:1,v/v) + 0.1% ammonium hydroxyde
Methanol
Methanol + 10mM ammonium acetate
Methanol + 0.1% ammonium hydroxyde
















4 5 6 7
i   / ( : )   .
i
. . . . . . . . .
%
:  f  ls  
   ( i r )
.





4 5 6 7
i   / ( : )_Make up MeOH+0.1%FA
i e




L 150817_078 9:  of 2 hannels  
163  103 ( inorex)
7.87e5






4 5 6 7
i   /ACN(1:1)_Make up MeOH+0.1%FA
Ti e




L 150817_078 9:  of 2 hannels + 
163 > 103 ( inorex)
7.87e5
4 5 6 7
ix 200 _ 2_ /ACN(1:1)_Make up eOH+0.1%FA
Ti e




L 150817_078 9:  of 2 hannels ES+ 
163 > 103 (A inorex)
7.87e5
4 5 6 7
i   /ACN(1:1)_Make up MeOH+0.1%FA
i
- . . . . . . . . .
%
7 8 :  f  l   
   ( i r )
7.8
4 5 6 7
i   /ACN(1:1)_Make up MeOH+0.1%FA
i
. . . . . . . . .
%
78 :  f  l   
   ( i r )
7.87
3 4
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4
Mix 200 pb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4
Mix 20  ppb_CEL _MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 1 3 (Aminorex)
7.87e5
3 4
Mix 2 0 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4
ix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up Me +0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0. %FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
5
Mix 200 ppb_CEL _MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 200 ppb_CEL _MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 2  ppb_CEL _MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 200 ppb_CEL _MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 200 ppb_CEL _MEOH/ACN(1:1)_Make up eOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 200 ppb_CEL _MEOH/ACN(1:1)_ ake up MeO +0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4
ix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+
163 > 10 (Aminorex)
7.87e5
3 4
Mix 200 ppb_CEL2_ EOH/ CN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4
Mix 2 0 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+
163 > 103 (Aminorex)
7.87e5
3 4
Mix 2  ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0 1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4
ix 200 ppb_CEL _MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4
Mix 200 ppb_CEL _MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4
Mix 20  ppb_CEL EOH/ACN(1:1)_Make up Me +0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
6 7 8
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
6 7 8
Mix 200 ppb_CEL2_ E /ACN(1:1)_Make up MeOH+ .1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
6 7 8
ix 2  ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
6 7 8
Mix  ppb_ EL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
6 7 8
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up eOH+ .1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
6 7 8
Mix 200 pb_CEL2_ EOH/ CN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
6 7 8
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
6 7 8
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
5 6




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
5 6
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
5 6
i   /ACN(1:1)_Make up eOH+0.1%FA
Ti e
-0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00
%
0
7 8 9:  f 2 l   
63 > 103 (Aminorex)
7.87
5 6
Mix 200 p b_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (A inorex)
7.87e5
5 6
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
i
- . . . . . . . . .
%
100
LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
5 6
i   / _Make up eOH+0.1%FA
i
. . . . . . . . .
%
78 9:  f 2 l   
163 > 103 (Aminorex)
7.87
5 6
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_07 9: MRM of 2 Chan els ES+ 
163 > 103 (Aminorex)
7.8 e5
5 6
i   / ( : )   .
i
- . . . . . . . . .
%
9:  f 2 l   
163 > 103 (Aminorex)
7.87 5
5 6 7
i   / ( : )   .
i
-0. . . . . . . . .
%
1 9:  f 2 l   
63 > 103 (Aminorex)
7.87
5 6 7
Mix 2  ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Cha nels ES+ 
163 > 103 (Ami or x)
7. 7e5
5 6 7
Mix 2 0 ppb CEL2_MEOH/ACN( :1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Cha nels ES+ 
163 > 103 (Ami or x)
7.87e5
5 6 7
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
5 6 7
ix 200 ppb_CEL2_ EOH/ACN(1:1)_ ake up MeOH+0.1%FA
Ti e




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
5 6 7
ix 200 _ 2_ /ACN(1:1)_Mak  up MeOH+0.1%FA
Ti e




L 50817_078 9:  of 2 hannels + 
163 > 103 (Aminorex)
7.87e5
5 6 7
Mix 200 pb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM 50817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
5 6 7
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 200 p b_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 200 ppb_CEL _MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 200 ppb_CEL2_MEOH/ CN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
 
Fig. S3. Effects of mobile phase composition on the enantioseparation of several cPACs in 
AMY (chromatographic conditions: mobile phase: CO2 (A’)/co-solvent (A-K) (B’); gradient: 
0 min – 95 % A’, 1 min – 95 % A’, 6 min – 40 % A’, 8.5 min – 40% A’, 8.7 min – 95 % A’, 
10 min – 95% A’;  flow: 1.5 mL/min; ABPR: 1800psi; make-up flow: methanol (0.1% formic 
acid) for positive ionization and methanol (0.2% ammonium hydroxide) for negative ionization 
at 0.3 mL min-1) 
  
Mix 200 ppb_MEOH/ACN(1:1)+10mM Am.Acetate_Make up MeOH+0.1%FA
Time




LCM150807_012 9: MRM of 2 Channels ES+ 








LCM150807_004 8: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
1.30e5
Mix 200 ppb_MEOH/ACN(1:1)+10mM Am.Acetate +0.1%FA_Make up MeOH+0.1%FA
Time




LCM150812_028 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
8.70e5
Mix 2 0 ppb_MEOH/IPA(1:1)_Make up MeOH+0.1%FA
Time




LCM150810_015 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
2.30e5
Mix 200 ppb_MEOH/IPA(1:1)+0.1%FA_Make up MeOH+0.1%FA
Time




LCM150810_023 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
3.05e5
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+0.1%FA_Make up MeOH+0.1%FA
Time




LCM150812_033 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
3.69e4
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+10mM Am. Acetate_Make up MeOH+0.1%FA
Time




LCM150810_020 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.36e4
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+20mM Am.Acetate_Make up MeOH+0.1%FA
Time




LCM150812_041 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
8.58e4
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+10mM Am.Acetate +0.1%FA_Make up MeOH+0.1%FA
Time




LCM150812_044 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
9.74e5
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+10mM Am.Acetate +0.1%NH4OH_Make up MeOH+0.1%FA
Time




LCM150812_036 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
5.63e5
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+10mM Am.Acetate +0.25%NH4OH_Make up MeOH+0.1%FA
Time




LCM150814_050 9: MRM of 2 Channels ES+ 































Mix 200 ppb_MEOH/IP /ACN(1:1:1)+10m  Am. Acetate_Make up MeOH+0.2%NH4
Time




LCM150810_019 14: MRM of 2 Channels ES- 
272 > 228 (Carprofen)
5.13e3
Mix 200 ppb_MEOH/ACN( :1)+10mM Am.Acetate +0.1%FA_Make up MeOH+0.2%NH4
Time




LCM150812_030 14: MRM of 2 Channels ES- 








LCM150807_007 14: MRM of 2 Channels ES- 
272 > 228 (Carprofen)
1.19e3
Mix 200 ppb_MEOH/IPA(1:1)_Make up MeOH+0.1%FA
Time




LCM150810_017 14: MRM of 2 Channels ES- 
272 > 228 (Carprofen)
3.03e3
Mix 200 ppb_MEOH/IPA(1:1)+0.1%FA_Make up MeOH+0.2%NH4
Time




LCM150810_025 14: MRM of 2 Channels ES- 
272 > 228 (Carprofen)
7.80e3
Mix 200 ppb_MEOH/IPA/ACN(1:1:1) . _Make up MeOH+0.2%NH4
Time




LCM150812_032 14: MRM of 2 Channels ES- 
272 > 228 (Carprofen)
1.55e4
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+20mM Am.Acetate_Make up MeOH+0.2%NH4
Time




LCM150812_040 14: MRM of 2 Channels ES- 
272 > 228 (Carprofen)
4.37e3
Mix 200 ppb_MEOH/IP /ACN(1:1: )+10m  Am.Acetate . _Make up MeOH+0.2%NH4
Time




LCM150812_046 14: MRM of 2 Channels ES- 
272 > 228 (Carprofen)
8.38e3
Mix 200 ppb_MEOH/IP /ACN(1:1: )+10mM Am.Acetate +0.1%NH4OH_Make up MeOH+0.2%NH4
Time




LCM150812_038 14: MRM of 2 Channels ES- 
272 > 228 (Carprofen)
3.08e3
Mix 200 ppb_MEOH/IP /ACN(1:1:1)+10mM Am.Acetate +0.25%NH4OH_Make up MeOH+0.2%NH4
Time




LCM150814_048 14: MRM of 2 Channels ES- 
272 > 228 (Carprofen)
3.94e3
Mix 200 ppb_MEOH+10mM Am.Acetate_Make up MeOH+0.2%NH4
Time




LCM150807_011 14: MRM of 2 Channels ES- 




Mix 200 ppb_MEOH+10mM Am.Acetate_Make up MeOH+0.2%NH4
Time




LCM150807_011 4: MRM of 2 Channels ES- 
320.8 > 151.8 (Chloramphenicol)
2.81e4
Mix 200 ppb_MEOH/ACN(1:1)+10mM Am.Acetate +0.1%FA_Make up MeOH+0.2%NH4
Time




LCM150812_030 4: MRM of 2 Channels ES- 








LCM15 807_007 4: MRM of 2 Channels ES- 
320.8 > 151.8 (Chloramphenicol)
2.54e4
Mix 200 ppb_MEOH/IPA(1:1)_Make up MeOH+0.1%FA
Time




LCM150810_017 4: MRM of 2 Channels ES- 
320.8 > 151.8 (Chloramphenicol)
1.12e5
Mix 200 ppb_MEOH/IPA(1:1)+0.1%FA_Make up MeOH+0.2%NH4
Time




LCM150810_025 4: MRM of 2 Channels ES- 
320.8 > 151.8 (Chloramphenicol)
1.37e5
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+0.1%FA_Make up MeOH+0.2%NH4
Time




LCM150812_032 4: MRM of 2 Channels ES- 
320.8 > 151.8 (Chloramphenicol)
1.03e5
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+10mM Am. Acetate_Make up MeOH+0.2%NH4
Time




LCM150810_019 4: MRM of 2 Channels ES- 
320.8 > 151.8 (Chloramphenicol)
1.09e5
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+20mM Am.Acetate_Make up MeOH+0.2%NH4
Time




LCM150812_040 4: MRM of 2 Channels ES- 
320.8 > 151.8 (Chloramphenicol)
1.14e5
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+10mM Am.Acetate +0.1%FA_Make up MeOH+0.2%NH4
Time




LCM150812_046 4: MRM of 2 Channels ES- 
320.8 > 151.8 (Chloramphenicol)
1.72e5
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+10mM Am.Acetate +0.1%NH4OH_Make up MeOH+0.2%NH4
Time




LCM150812_038 4: MRM of 2 Channels ES- 
320.8 > 151.8 (Chloramphenicol)
9.64e4
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+10mM Am.Acetate +0.25%NH4OH_Make up MeOH+0.2%NH4
Time




LCM150814_048 4: MRM of 2 Channels ES- 









Mix 200 ppb_MEOH/ACN(1:1)+10mM Am.Acetate_Make up MeOH+0.1%FA
Time




LCM150807_012 11: MRM of 2 Channels ES+ 
198.9 > 77.9 (N-Dechloroethyl cyclophosphamide)
3.81e4
Mix 2 0 ppb
Time




LCM150807_004 10: MRM of 2 Channels ES+ 
198.9 > 77.9 (N-Dechloroethyl cyclophosphamide)
1.83e5
Mix 200 ppb_MEOH/ACN(1:1)+10mM Am.Acetate +0.1%FA_Make up MeOH+0.1%FA
Time




LCM150812_028 11: MRM of 2 Channels ES+ 
198.9 > 77.9 (N-Dechloroethyl cyclophosphamide)
7.97e5
Mix 2  ppb_MEOH/IPA(1:1)_Make up MeOH+0.1%FA
Time




LCM150810_015 11: MRM of 2 Channels ES+ 
198.9 > 77.9 (N-Dechloroethyl cyclophosphamide)
5.83e5
Mix 200 ppb_MEOH/IPA(1:1)+0.1%FA_Make up MeOH+0.1%FA
Time




LCM150810_023 11: MRM of 2 Channels ES+ 
198.9 > 77.9 (N-Dechloroethyl cyclophosphamide)
6.15e5
Mix 2  ppb_MEOH/IPA/ACN(1:1:1)+0.1%FA_Make up MeOH+0.1%FA
Time




LCM150812_033 11: MRM of 2 Channels ES+ 
198.9 > 77.9 (N-Dechloroethyl cyclophosphamide)
6.82e4
Mix 2 0 ppb_MEOH/IPA/ACN(1:1:1)+10mM Am. Acetate_Make up MeOH+0.1%FA
Time




LCM150810_020 11: MRM of 2 Channels ES+ 
198.9 > 77.9 (N-Dechloroethyl cyclophosphamide)
5.33e4
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+20mM Am.Acetate_Make up MeOH+0.1%FA
Time




LCM150812_041 11: MRM of 2 Channels ES+ 
198.9 > 77.9 (N-Dechloroethyl cyclophosphamide)
7.60e4
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+10mM Am.Acetate +0.1%FA_Make up MeOH+0.1%FA
Time




LCM150812_044 11: MRM of 2 Channels ES+ 
198.9 > 77.9 (N-Dechloroethyl cyclophosphamide)
9.83e5
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+10mM Am.Acetate .1 OH_Make up MeOH+0.1%FA
Time




LCM150812_036 11: MRM of 2 Channels ES+ 
198.9 > 77.9 (N-Dechloroethyl cyclophosphamide)
7.66e5
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+10m  Am.Acetate +0.25 OH_Make up MeOH+0.1%FA
Time




LCM150814_050 11: MRM of 2 Channels ES+ 













Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+10mM Am.Acetate +0.25%NH4OH_Make up MeOH+0.2%NH4
Time




LCM150814_048 13: MRM of 1 Channel ES- 
243 > 199 (Flurbiprofen)
1.39e4
Mix 200 ppb_MEOH+1 mM Am.Acetate_Make up MeOH+0.2%NH4
Time




LCM150807_011 13: MRM of 1 Channel ES- 
243 > 199 (Flurbiprofen)
4.63e3
Mix 200 ppb_MEOH/ACN(1:1)+10mM Am.Acetate +0.1%FA_Make up MeOH+0.2%NH4
Time




LCM150812_030 13: MRM of 1 Channel ES- 








LCM150807_007 13: MRM of 1 Channel ES- 
243 > 199 (Flurbiprofen)
6.51e3
Mix 200 ppb_MEOH/IPA(1:1)_Make up MeOH+0.1%FA
Time




LCM150810_017 13: MRM of 1 Channel ES- 
243 > 199 (Flurbiprofen)
1.80e4
Mix 200 ppb_MEOH/IPA(1:1)+0.1%FA_Make up MeOH+0.2%NH4
Time




LCM150810_025 13: MRM of 1 Channel ES- 
243 > 199 (Flurbiprofen)
1.57e4
Mix 2 0 ppb_MEOH/IPA/ACN(1:1:1)+ .1%FA_Make up MeOH+0.2%NH4
Time




LCM150812_032 13: MRM of 1 Channel ES- 
243 > 199 (Flurbiprofen)
1.85e4
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+10mM Am. Acetate_Make up MeOH+0.2%NH4
Time




LCM150810_019 13: MRM of 1 Channel ES- 
243 > 199 (Flurbiprofen)
1.11e4
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+20mM Am.Acetate_Make up MeOH+0.2%NH4
Time




LCM150812_040 13: MRM of 1 Channel ES- 
243 > 199 (Flurbiprofen)
1.22e4
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+10mM Am.Acetate +0.1%FA_Make up MeOH+0.2%NH4
Time




LCM150812_046 13: MRM of 1 Channel ES- 
243 > 199 (Flurbiprofen)
1.74e4
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+10mM Am.Acetate +0.1%NH4OH_Make up MeOH+0.2%NH4
Time




LCM150812_038 13: MRM of 1 Channel ES- 













Mix 200 ppb_MEOH+10mM Am.Acetate_Make up MeOH+0.2%NH4
Time




LCM150807_011 6: MRM of 2 Channels ES- 
221 > 177 (2-Hydroxyibuprofen)
5.23e3
Mix 200 ppb_MEOH/ACN(1:1)+10mM m.Ac tate +0.1%FA_Make up MeOH+0.2%NH4
Time




LCM150812_030 6: MRM of 2 Channels ES- 








LCM150807_ 07 6: MRM of 2 Channels ES- 
221 > 177 (2-Hydroxyibuprofen)
1.22e4
Mix 200 ppb_MEOH/IPA(1: )_Make up MeOH+0.1%FA
Time




LCM150810_017 6: MRM of 2 Channels ES- 
221 > 177 (2-Hydroxyibuprofen)
1.79e4
Mix 200 ppb_MEOH/IPA(1:1)+0.1%FA_Make up MeOH+0.2%NH4
Time




LCM150810_025 6: MRM of 2 Channels ES- 
221 > 177 (2-Hydroxyibuprofen)
1.32e4
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+0.1%FA_Make up MeOH+0.2%NH4
Time




LCM150812_032 6: MRM of 2 Channels ES- 
221 > 177 (2-Hydroxyibuprofen)
1.05e4
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+10mM Am. Acetate_Make up MeOH+0.2%NH4
Time




LCM150810_019 6: MRM of 2 Channels ES- 
221 > 177 (2-Hydroxyibuprofen)
1.30e4
ix 200 ppb_MEOH/IPA/ACN(1:1:1)+20mM Am.Acetate_Make up MeOH+0.2%NH4
Time




LCM150812_040 6: MRM of 2 Channels ES- 
221 > 177 (2-Hydroxyibuprofen)
1.32e4
ix 200 ppb_MEOH/IP /ACN(1:1:1) 10mM m.Ac tate +0.1%FA_Make up MeOH+0.2%NH4
Time




LCM150812_046 6: MRM of 2 Channels ES- 
221 > 177 (2-Hydroxyibuprofen)
7.71e3
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+10mM Am.Acetate +0.1%NH4OH_Make up MeOH+0.2%NH4
Time




LCM150812_038 6: MRM of 2 Channels ES- 
221 > 177 (2-Hydroxyibuprofen)
1.14e4
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+10mM Am.Acetate +0.25%NH4OH_Make up MeOH+0.2%NH4
Time




LCM150814_048 6: MRM of 2 Channels ES- 












Mix 200 ppb_MEOH/ACN(1:1)+10mM Am.Acetate_Make up MeOH+0.1%FA
Time




LCM150807_012 4: MRM of 4 Channels ES+ 








LCM150807_004 3: MRM of 4 Channels ES+ 
261 > 91.95 (Ifosfamide)
5.57e4
Mix 200 ppb_MEOH/AC (1:1)+10mM Am.Acetate +0.1%FA_Make up MeOH+0.1%FA
Time




LCM150812_028 4: MRM of 4 Channels ES+ 
261 > 91.95 (Ifosfamide)
4.95e5
ix 2 0 ppb_MEOH/IPA(1:1)_Make up MeOH+0.1%FA
Time




LCM150810_015 4: MRM of 4 Channels ES+ 
261 > 91.95 (Ifosfamide)
3.68e5
ix 200 ppb_MEOH/IPA(1:1)+0.1%FA_Make up MeOH+0.1%FA
Time




LCM150810_023 4: MRM of 4 Channels ES+ 
261 > 91.95 (Ifosfamide)
4.55e5
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+0.1%FA_Make up MeOH+0.1%FA
Time




LCM150812_033 4: MRM of 4 Channels ES+ 
261 > 91.95 (Ifosfamide)
4.28e4
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+1 mM Am. Acetate_Make up MeOH+0.1%FA
Time




LCM150810_020 4: MRM of 4 Channels ES+ 
261 > 91.95 (Ifosfamide)
3.50e4
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+20mM Am.Acetate_Make up MeOH+0.1%FA
Time




LCM150812_041 4: MRM of 4 Channels ES+ 
261 > 91.95 (Ifosfamide)
4.70e4
Mix 200 ppb_MEOH/IPA/ CN(1:1:1)+10mM Am.Acetate +0.1%FA_Make up MeOH+0.1%FA
Time




LCM150812_044 4: MRM of 4 Channels ES+ 
261 > 91.95 (Ifosfamide)
6.28e5
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+10mM Am.Acetate +0.1%NH4OH_Make up MeOH+0.1%FA
Time




LCM150812_036 4: MRM of 4 Channels ES+ 
261 > 91.95 (Ifosfamide)
4.86e5
Mix 200 ppb_ EOH/IPA/ACN(1:1:1)+10mM Am.Acetate +0.25%NH4OH_Make up MeOH+0.1%FA
Time




LCM150814_050 4: MRM of 4 Channels ES+ 













Mix 200 ppb_MEOH+10mM Am.Acetate_Make up MeOH+0.2%NH4
Time




LCM150807_011 11: MRM of 3 Channels ES- 
228.85 > 185.26 (Naproxen)
5.11e3
Mix 200 ppb_MEOH/ACN(1:1)+10mM Am.Acetate +0.1%FA_Make up MeOH+0.2%NH4
Time




LCM150812_030 11: MRM of 3 Channels ES- 








LCM15 8 7_007 11: MRM of 3 Channels ES- 
228.85 > 185.26 (Naproxen)
7.24e3
Mix 200 ppb_MEOH/IPA(1:1)_Make up MeOH+ .1%FA
Time




LCM150810_017 11: MRM of 3 Channels ES- 
228.85 > 185.26 (Naproxen)
2.62e4
Mix 20  ppb_MEOH/IPA(1:1)+0.1%FA_Make up MeOH+0.2%NH4
Time




LCM150810_025 11: MRM of 3 Channels ES- 
228.85 > 185.26 (Naproxen)
1.27e4
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+0.1%FA_Make up MeOH+0.2%NH4
Time




LCM150812_032 11: MRM of 3 Channels ES- 
228.85 > 185.26 (Naproxen)
1.03e4
Mix 200 ppb_MEO /IPA/ACN(1:1:1)+10mM Am. Acetate_Make up MeOH+ .2%NH4
Time




LCM150810_019 11: MRM of 3 Channels ES- 
228.85 > 185.26 (Naproxen)
3.19e4
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+20mM Am.Acetate_Make up MeOH+0.2%NH4
Time




LCM150812_040 11: MRM of 3 Channels ES- 
228.85 > 185.26 (Naproxen)
3.60e4
Mix 00 ppb_MEOH/IP /AC (1:1:1)+10mM Am.Acetate +0.1%FA_Make up MeOH+0.2%NH4
Time




LCM150812_046 11: MRM of 3 Channels ES- 
228.85 > 185.26 (Naproxen)
8.41e3
Mix 2 0 ppb_MEOH/IPA/ACN(1:1:1)+ 0mM Am.Acetate +0.1%NH4OH_Make up MeOH+0.2%NH4
Time




LCM150812_038 11: MRM of 3 Channels ES- 
228.85 > 185.26 (Naproxen)
3.10e4
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+10mM Am.Acet t  +0.25%NH4OH_Make up MeOH+0.2%NH4
Time




LCM150814_048 11: MRM of 3 Channels ES- 




Mix 200 ppb_MEOH/ACN(1:1)+10mM Am.Acetate_Make up MeOH+0.1%FA
Time




LCM150807_012 12: MRM of 3 Channels ES+ 








LCM150807_004 11: MRM of 3 Channels ES+ 
346.1 > 136.06 (Omeprazole)
7.19e4
ix 200 ppb_MEOH/ACN(1:1)+10mM Am.Acetate +0.1%FA_Make up MeOH+0.1%FA
Time




LCM15 812_028 12: MRM of 3 Channels ES+ 
346.1 > 136.06 (Omeprazole)
1.80e5
Mix 200 pb_MEOH/IPA(1:1)_Mak  up MeOH+0.1%FA
Time




LCM150810_015 12: MRM of 3 Channels ES+ 
346.1 > 136.06 (Omeprazole)
3.26e5
Mix 200 ppb_MEOH/IPA(1:1)+0.1%FA_Make up MeOH+0.1%FA
Time




LCM1508 0_023 12: MRM of 3 Channels ES+ 
346.1 > 136.06 (Omeprazole)
3.81e5
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+ 1%FA_Make up MeOH+ .1%FA
Time




LCM150812_033 12: MRM of 3 Channels ES+ 
346.1 > 198.1 (Omeprazole)
1.86e5
Mix 2  ppb_MEOH/IPA/ACN( :1:1)+10mM Am. Acetat _Mak  up MeOH+0.1%FA
Time




LCM150810_020 12: MRM of 3 Channels ES+ 
346.1 > 198.1 (Omeprazole)
1.90e5
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+20mM Am.Acetate_Make up MeOH+0.1%FA
Time




LCM150812_041 12: MRM of 3 Channels ES+ 
346.1 > 198.1 (Omeprazole)
1.57e5
Mix 200 ppb_MEOH/IPA/ACN( :1:1)+10mM Am.Acetate +0.1%FA_ ake up MeO +0.1%FA
Time




LCM150812_044 12: MRM of 3 Channels ES+ 
346 1 > 136.06 (Omeprazole)
3.46e5
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+10m  Am.Acetate 0.1 NH4OH_Make up MeOH+0.1%FA
Time




LCM1508 2_036 12: MRM of 3 Channels ES+ 
346.1 > 198.1 (Omeprazole)
5.34e5
Mix 200 ppb_ E H/IPA/ACN(1:1:1)+10mM Am.Acetate +0.25 NH4OH_Make up MeOH+0.1%FA
Time




LCM150814_050 12: MRM of 3 Channels ES+ 











Mix 2 0 ppb_MEOH/ACN(1:1)+10mM Am.Acetate_Make up MeOH+0.1%FA
Time




LCM150807_012 15: MRM of 4 Channels ES+ 








LCM150807_004 14: MRM of 4 Channels ES+ 
313.1 > 83 (Praziquantrel)
2.15e3
Mix 200 ppb_MEOH/ACN(1:1)+10mM Am.Acetate +0.1%FA_Make up MeOH+0.1%FA
Time




LCM150812_028 15: MRM of 4 Channels ES+ 
313.1 > 83 (Praziquantrel)
8.15e4
Mix 200 p b_MEOH/IPA(1:1)_Make up MeOH+0.1%FA
Time




LCM150810_015 15: MRM of 4 Channels ES+ 
313.1 > 83 (Praziquantrel)
4.45e4
Mix 200 ppb_ E H/IPA(1:1)+0.1%FA_Make up MeOH+0.1%FA
Time




LCM150810_023 15: MRM of 4 Channels ES+ 
313.1 > 83 (Praziquantrel)
7.93e4
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+ .1%FA_Make up MeOH+0.1%FA
Time




LCM150812_033 15: MRM of 4 Channels ES+ 
313.1 > 203 (Praziquantrel)
5.23e4
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+10mM Am. Acetate_Make up MeOH+0.1%FA
Time




LCM150810_020 15: MRM of 4 Channels ES+ 
313.1 > 83 (Praziquantrel)
2.36e4
Mix 200 p b_MEOH/IP /ACN(1:1:1)+20m  Am.Acetate_Make up MeOH+0.1%FA
Time




LCM150812_041 15: MRM of 4 Channels ES+ 
313.1 > 83 (Praziquantrel)
3.11e4
Mix 200 ppb_MEOH/IP /ACN(1:1:1)+10mM Am.Acetate +0.1%FA_Make up MeOH+0.1%FA
Time




LCM150812_044 15: MRM of 4 Channels ES+ 
313.1 > 83 (Praziquantrel)
1.57e5
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+10mM Am.Acetate +0.1%NH4OH_Make up MeOH+0.1%FA
Time




LCM150812_036 15: MRM of 4 Channels ES+ 
313.1 > 83 (Praziquantrel)
9.79e4
Mix 2 0 ppb_MEOH/IPA/ACN(1:1:1)+10mM Am.Ac tate +0.25%NH4OH_Make up MeOH+0.1%FA
Time




LCM150814_050 15: MRM of 4 Channels ES+ 














Mix 200 ppb_MEOH/ACN(1:1)+10mM Am.Acetate_Make up MeOH+0.1%FA
Time




LCM150807_012 2: MRM of 4 Channels ES+ 








LCM150807_004 1: MRM of 4 Channels ES+ 
205 > 91 (Tetramisole HCl)
5.93e5
Mix 200 ppb_MEOH/ACN(1:1)+10mM Am.Acetate +0.1%FA_Make up MeOH+0.1%FA
Time




LCM150812_028 2: MRM of 4 Channels ES+ 
205 > 91 (Tetramisole HCl)
8.33e5
Mix 200 ppb_MEOH/IPA(1:1)_Make up MeOH+0.1%FA
Time




LCM150810_015 2: MRM of 4 Channels ES+ 
205 > 91 (Tetramisole HCl)
9.91e5
Mix 200 ppb_MEOH/IPA(1:1)+0.1%FA_Make up MeOH+0.1%FA
Time




LCM150810_023 2: MRM of 4 Channels ES+ 
205 > 91 (Tetramisole HCl)
8.55e5
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+0.1%FA_Make up MeOH+0.1%FA
Time




LCM150812_033 2: MRM of 4 Channels ES+ 
205 > 91 (Tetramisole HCl)
1.99e5
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+10mM Am. Acetate_Make up MeOH+0.1%FA
Time




LCM150810_020 2: MRM of 4 Channels ES+ 
205 > 91 (Tetramisole HCl)
3.74e5
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+20mM Am.Acetate_Make up MeOH+0.1%FA
Time




LCM150812_041 2: MRM of 4 Channels ES+ 
205 > 91 (Tetramisole HCl)
3.57e5
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+10mM Am.Acetate +0.1%FA_Make up MeOH+0.1%FA
Time




LCM150812_044 2: MRM of 4 Channels ES+ 
205 > 91 (Tetramisole HCl)
1.19e6
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+10mM Am.Acetate +0.1%NH4OH_Make up MeOH+0.1%FA
Time




LCM150812_036 2: MRM of 4 Channels ES+ 
205 > 91 (Tetramisole HCl)
1.25e6
Mix 200 ppb_MEOH/IPA/ACN(1:1:1)+10mM Am.Acetate +0.25%NH4OH_Make up MeOH+0.1%FA
Time




LCM150814_050 2: MRM of 4 Channels ES+ 











Methanol/Acetonitrile (1:1, v/v) + 10mM ammonium acetate
Methanol/Acetonitrile (1:1, v/v) + 10mM ammonium acetate + 0.1% formic acid
Methanol
Methanol/isopropanol (1:1, v/v)
Methanol/isopropanol (1:1, v/v) + 0.1% formic acid
Methanol/isopropanol/acetonitrile (1:1:1, v/v/v) + 0.1% formic acid
Methanol/isopropanol/acetonitrile (1:1:1, v/v/v) + 10mM ammonim acetate
Methanol/isopropanol/acetonitrile (1:1:1, v/v/v) + 20mM ammonium acetate
Methanol/isopropanol/acetonitrile (1:1:1, v/v/v) + 10mM ammonium acetate + 0.1% formic acid
Methanol/isopropanol/acetonitrile (1:1:1, v/v/v) + 10mM ammonium acetate + 0.1% ammonium hydroxyde



















3 4 5 6
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4 5 6
Mix 200 ppb_CEL _MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4 5 6
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0. %FA
Time




LCM150817_078 9: MRM of 2 Channels ES+
163 > 103 (Aminorex)
7.87e5
3 4 5 6
Mix 2 0 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+
163 > 103 (Aminorex)
7.87e5
3 4 5 6
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4 5 6
Mix 2 0 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4 5 6
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4 5 6
Mix 200 ppb_CEL _MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4 5 6
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4 5 6
Mix 200 ppb_CEL _MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4 5 6
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
5 6 7
ix 200 ppb_CEL2_ E /ACN(1:1)_ ake up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
5 6 7
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
5 6 7
Mix 20  ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
5 6 7
Mix 20  ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0 1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
5 6 7
ix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
5 6 7
ix 2 0 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+ 1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
5 6 7
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
5 6 7
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
5 6 7
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_ ake up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
5 6 7
ix 200 ppb_ EL2_MEO /ACN(1:1)_M ke up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
5 6 7
ix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_ ake up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 2  ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 20  pb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 2 0 pb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 2  ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%F
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 200 pb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 200 pb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 200 pb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 200 pb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+
163 > 103 (Aminorex)
7.87e5
4 5
i   CEL2_ E /ACN(1:1)_Make up M OH+0.1%FA
i





163 > 103 (Aminorex
7 7 5
4 5
ix 200 ppb_C L2_MEOH/ CN(1:1)_Make up MeOH+0.1%FA
i
- . . . . .
%
100
LC 150817_078 9: R  of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 20  p b_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Chan els ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
i  0  CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA




L 150817_078 9:  f  l   
163 > 103 (Aminorex)
7. 7
4 5
i   CEL2_MEOH/AC (1:1)_Make up MeOH+0.1%FA





163 > 103 (Aminorex
7 87
4 5
i  0 C L2_MEOH/ACN(1:1)_Make up MeOH+ .1%FA
Ti e
- . . . .0 7.00 8. 0
%
100
L 150817_078 9:  of 2 hannels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
i   CEL2_MEOH/ACN( : )_Make up MeOH+ .1%FA
i




L 150817_078 9:  f  ls  
163 > 103 (Aminorex)
7.87 5
4 5
C L2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Ti e
-0 1 2 3.00 4.00 5.0 6.00 7.00 8. 0
%
7 78 9:  of 2 hannels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 2 0 pb_CEL2_MEOH/ACN( :1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Cha nels ES+ 
163 > 103 (Aminor x)
7.87e5
4 5
Mix 20  ppb_CEL2_MEOH/ACN( _Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 20  ppb_CEL2_MEOH/ACN( _Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_ ake up e 0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up e +0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up e +0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up e +0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+
163 > 103 (Aminorex)
7.87e5
3 4
Mix 2 0 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up e +0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4
Mix 0 ppb_CEL2_MEOH/ACN(1:1)_Make up e +0.1%F
Time




LCM150817_078 9: MRM of 2 Channels ES+
163 > 103 (Aminorex)
7.87e5
3 4
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up e +0.1%F
Time




LCM150817_078 9: MRM of 2 Channels ES+
163 > 103 (Aminorex)
7.87e5
3 4
Mix 20  ppb_CEL2_MEOH/AC (1:1)_Make up e +0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4
Mix 20  ppb_CEL2_MEOH/ACN(1:1)_Make up eOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
i   C L2_MEOH/ CN(1:1)_ ake up MeOH+0.1%FA
i
- . . . . . . . . .
%
1 78 9:  of 2 hannels ES+
163 > 103 (Amin r x
7 87 5
4 5
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Ti e




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 200 ppb_CEL2_MEOH/ CN(1:1)_ ake up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 2 0 ppb_C L2_MEOH/ CN(1:1)_Make up MeOH+0.1%FA
Ti e




LCM150817_078 9:  f  l  + 
163 > 103 (Aminorex)
7.87e5
4 5
C L2_MEOH/ CN(1:1)_Make up MeOH+0.1%FA
i e
. . . . . .
%
7 78 9: RM of 2 Chan els ES+ 
163 > 103 (Amin r x)
7.87e5
4 5
Mix 2 0 ppb_CEL2_MEOH/ CN(1:1)_Make up MeOH+0 1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
ix 200 ppb_C L2_ EOH/ CN(1:1)_ ake up MeOH+0.1%F
Ti e




LCM150817_078 9:  f  ls + 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 20  ppb_C L2_ EOH/ CN(1:1)_Make up MeOH+0.1%FA
Ti e




LCM150817_078 9:  f  l  + 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 200 ppb_C L2_ EOH/ CN(1:1)_Make up MeOH+0.1%FA
Ti e




LCM150817_078 9 + 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 200 ppb_C L2_ EOH/ CN(1:1)_Make up MeOH+0.1%FA
Ti e




LCM150817_078 9:  f  ls + 
163 > 103 (Aminorex)
7.87e5
4 5
i   C L2_MEOH/ CN(1:1)_Make up MeOH+0.1%FA
i e
. . . . . . 8.00
%
7 7 9: MRM of 2 Chan els ES+ 
163 > 103 (Aminor x)
7.87e5
3 4
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
i   C L2_MEOH/ACN(1:1)_Make u  MeOH+0.1%FA
i
. . . .
%
1 78 9:  f 2 l  + 
163 > 103 (Aminor x)
7.87 5
5 6 7
ix 200 ppb_CEL _MEOH/ACN(1: )_ ake up e H+0.1 F
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
6 7 8
Mix 20  ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LC 150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4 5
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make u  MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 200 ppb_CEL _MEOH/ACN(1:1)
Time




LCM150817_078 9: MRM of 2 Chan els ES+ 
163 > 03 (Aminorex)
7.8 e5
5 6 7
ix 200 ppb_CEL2_MEOH/ACN( : )_Make up eOH+0.1%F
Time




LCM150817_078 9: MRM of  Channels ES+ 
163 > 103 (Aminorex)
7.87e5
6 7 8
ix 200 ppb_CEL2_MEOH/ACN( :1)_Make up MeOH+0.1%FA
Time




LC 150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4 5
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make u  MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
5 6 7
Mix 200 ppb_CEL _MEOH/ACN(1: )_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
6 7 8
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LC 150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4 5
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4
Mix 2  ppb_CEL2_MEOH/ CN(1:1)_Make u  MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 200 ppb_CEL2_MEOH/ACN( : )   .
Time




LCM150817_078 9: MRM of 2 Chan els ES+ 
163 > 103 (Amin rex)
7.87e5
5 6 7
ix 200 ppb_CEL _MEOH/ACN(1: )_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
6 7 8
Mix 200 ppb_CEL2_MEOH/ CN(1:1)_Make up MeOH+0.1%FA
Time




LC 150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4 5
Mix 200 ppb_CEL _MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4
Mix 200 ppb CEL2_MEOH/ACN(1:1)_Make u  MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 200 ppb_CEL2_MEOH/ACN( : )_Make u  eOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Chan els ES+ 
16  > 103 (Amin rex)
7.87e5
5 6 7
ix 200 ppb_CEL _MEOH/ACN(1: )_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
6 7 8
Mix 200 ppb CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LC 150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4 5
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4
ix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+ .1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 2  ppb_CEL2_MEOH/ACN(1:1)_Make up eOH+0.1%F
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
5 6 7
ix 2  ppb_CEL2_MEOH/ACN(1: )_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
6 7 8
Mix 2 0 ppb_CEL2_ EOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LC 150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4 5
Mix 2  ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+
163 > 103 (Aminorex)
7.87e5
3 4
Mix  ppb_CEL2_MEOH/ACN(1:1)_Make u  MeOH+ .1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 200 ppb_CEL2_MEOH/ACN( : )_Make up MeOH+ .1%FA
Time




LCM150817_078 9: MRM of 2 Chan els ES+ 
16  > 103 (Amin rex)
7.87e5
5 6 7
ix 2  ppb_CEL2_ EOH/ CN(1: )_Make up MeOH+ .1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
6 7 8
Mix 2  ppb_CEL2_MEOH/ CN(1:1)_Make up MeOH+0 1%FA
Time




LC 150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4 5
Mix 200 ppb_CEL _MEOH/ACN(1:1)_Make up MeOH+0 1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4
Mix 200 ppb_CEL2_ E /ACN(1:1)_Make up MeOH+0.1%F
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
ix 200 _C L2_ EOH/ACN(1:1)_Make up e +0.1%FA
Time




L 150817_078 9:  of 2 hannels ES+ 
163 > 103 (Aminorex)
7.87e5
5 6 7
ix 200 ppb_CEL2_ EOH/ACN(1: )_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
6 7 8
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_ ake up MeOH+0.1%FA
Time




LC 150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4 5
Mix 200 ppb_CEL _MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4
Mix 200 ppb_CEL2_ EOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM 50817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
Mix 2 0 pb_CEL2_MEOH/ACN( :1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Cha nels ES+ 
163 > 103 (Aminorex)
7.87e5
5 6 7
ix 200 ppb_CEL2_MEOH/ACN(1: )_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
6 7 8
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LC 150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4 5
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4
Mix 200 ppb_CEL _MEOH/ACN(1:1)_Make up MeOH+0.1%F
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
i
- . . . . . . . . .
%
100
LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
5 6 7
Mix 200 ppb_CEL2_MEOH/ACN(1: )_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
6 7 8
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4 5
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4
Mix 200 ppb_CEL2_MEOH/ACN(1:1)_Make up MeOH+0.1%F
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
4 5
i   C L2_MEOH/ACN(1:1)_Make up Me +0.1%FA
i
. . . .
%
7 7 9:  f 2 l  + 
163 > 103 (Aminor x)
7.87 5
5 6 7
ix 200 ppb_CEL2_ EOH/ACN(1: )_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 10  (Aminorex)
7.87e5
6 7 8
Mix 200 ppb_CEL2_ E /ACN(1:1)_Make up MeOH+0.1%FA
Time




LC 150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
3 4 5
Mix 200 pb_CEL _MEOH/ACN(1:1)_Make up MeOH+0.1%FA
Time




LCM150817_078 9: MRM of 2 Channels ES+ 
163 > 103 (Aminorex)
7.87e5
Table S1 
Optimized MRM transitions for the target cPACs by UHPSFC-MS/MS and pKa values. 










20 ESI+ 7.49 
R/S(±)-Carboxyibuprofen 





25 ESI- 4.77 




48 ESI- 4.42 











20 ESI+ 13.58 




27 ESI- 13.58 




30 ESI+ 13.04 
S-(+)-O-Desmethylnaproxen (M)d 215.0 170.5b 10 20 ESI- 4.34, 9.78 
R/S(±)-Dihydroketoprofen (M) 255.0 211.0b 8 30 ESI- 4.30, 13.73 




50 ESI-  3.96 




33 ESI+ 4.04, 9.01, 13.20 
R/S(±)-Flurbiprofen 243.0 199.0b 10 30 ESI- 4.42 
R/S(±)-2-Hydroxyibuprofen (M) 221.0 177.0b 6 30 ESI- 4.63 
R/S(±)-Ibuprofen 204.9 161.5b 6 26 ESI- 4.85 




40 ESI+ 13.94 




40 ESI+ 6.77 




45 ESI+ 3.74 




35 ESI+ 3.88 




28 ESI+ 4.19 




56 ESI+ 5.45 




20 ESI+ 1.59, 4.77, 9.68 
R/S(±)-2-Phenylpropionic acid (M) 149.0 105.0b 5 20 ESI- 4.59 




50 ESI+ 6.98 




40 ESI+ n.a. 
CE: Collision energy; CV: Cone voltage; R/S(±): Racemic mixture; M: metabolite;aChemaxon predicted values; bQuantification; 
cConfirmation; dCompound sold as enantiomerically pure; n.a.: not available 
  
Table S2 
Chromatographic parameters for each cPAC obtained under different mobile phase composition with AMY CSP 








(1:1, v/v) + 
10mM NH4OAc + 








(1:1, v/v) * 
0.1% formic acid 
F: 
MeOH/IPA/ACN 
(1:1:1, v/v/v) + 
0.1% formic acid 
 k1 k2 α RS k1 k2 α RS k1 k2 α RS k1 k2 α RS k1 k2 α RS k1 k2 α RS 
R/S(±)-Aminorex - - - - - - - - 0.93 0.94 1.02 1.00 - - - - - - - - - - - - 
R/S(±)-Carboxyibuprofen -a -a -a -a - - - - -a -a -a -a - - - - - - - - - - - - 
R/S(±)-Carprofen -a -a -a -a 0.95 0.95 1.00 1.20 -a -a -a -a - - - - 0.96 0.96 1.00 0.70 - - - - 
R/S(±)-Cetirizine  - - - - - - - - - - - - - - - - - - - - - - - - 
1S,2S-(+)-Chloramphenicol + 
1R,2R-(-)-Chloramphenicol 
0.94 0.94 1.00 0.84 0.94 0.94 1.00 0.92 0.94 0.95 1.00 0.89 - - - - - - - - 0.94 0.94 1.00 0.80 
R/S(±)-3-N-Dechloroethyl 
ifosfamide  
0.94 0.95 1.01 6.30 0.94 0.96 1.01 6.55 0.94 0.95 1.01 3.94 0.94 0.95 1.01 3.56 0.94 0.95 1.01 3.85 0.94 0.95 1.01 5.40 
S-(+)-O-Desmethylnaproxen -a -a -a -a -a -a -a -a -a -a -a -a - - - - - - - - - - - - 
R/S(±)-Dihydroketoprofen - - - - - - - - - - - - - - - - - - - - - - - - 
R/S(±)-Fenoprofen - - - - - - - - - - - - - - - - - - - - - - - - 
R/S(±)-Fexofenadine  - - - - - - - - - - - - -a -a -a -a -a -a -a -a - - - - 
R/S(±)-Flurbiprofen 0.94 0.94 1.00 0.95 0.93 0.93 1.00 1.20 -a -a -a -a 0.94 0.94 1.00 0.88 0.93 0.94 1.00 1.50 0.93 0.93 1.00 1.20 
R/S(±)-2-Hydroxyibuprofen -a -a -a -a 0.94 0.94 1.00 1.10 -a -a -a -a 0.94 0.94 1.00 0.56 0.94 0.94 1.00 1.00 0.94 0.94 1.00 1.13 
R/S(±)-Ibuprofen - - - - -a -a -a -a -a -a -a -a - - - - -a -a -a -a - - - - 
R/S(±)-Ifosfamide  0.93 0.94 1.00 1.00 0.93 0.94 1.00 1.60 0.93 0.94 1.00 1.00 0.93 0.94 1.00 1.20 0.93 0.94 1.01 1.55 0.93 0.94 1.00 1.92 
R/S(±)-Imazalil - - - - - - - - - - - - - - - - - - - - - - - - 
R/S(±)-Indoprofen - - - - - - - - - - - - - - - - - - - - - - - - 
R/S(±)-Ketoprofen - - - - - - - - - - - - - - - - - - - - - - - - 
R/S(±)-Naproxen 0.94 0.94 1.00 0.75 -a -a -a -a -a -a -a -a - - - - - - - - - - - - 
R/S(±)-Ofloxacin  -a -a -a -a - - - - -a -a -a -a -a -a -a -a -a -a -a -a -a -a -a -a 
R/S(±)-Omeprazole  0.96 0.96 1.00 0.64 0.96 0.96 1.00 0.92 0.96 0.96 1.00 0.82 - - - - - - - - 0.96 0.96 1.00 0.96 
R/S(±)-Phenylpropionic acid  - - - - -a -a -a -a -a -a -a -a - - - - -a -a -a -a -a -a -a -a 
R/S(±)-Praziquantel 0.96 0.97 1.01 3.00 0.96 0.97 1.01 6.00 -a -a -a -a 0.96 0.97 1.01 3.00 0.96 0.97 1.01 2.02 0.96 0.96 1.00 1.84 
R/S(±)-Tetramisole  - - - - 0.94 0.94 1.00 0.75 - - - - - - - - - - - - - - - - 
MeOH: methanol; ACN: acetonitrile; IPA: isopropanol; NH4OAc: ammonium acetate; - : no resolution; 
ano peak; k1: retention factor of the first eluted peak; k2: retention factor of the second eluted peak; α: selectivity 
factor; RS: resolution 
k’=(tR-t0)/t0  where tR is the retention time of each enantiomer (first or second) and t0 is the retention time of an unretained compound. 
α=k’2/k’1   where k’2 and k’1 are the capacity factors of the second and first eluting enantiomers, respectively. 
Rs=2(tR2-tR1)/(w1+w2)  where tR1 and tR2 are the retention times of the first and the second eluting enantiomers, respectively, and w1 and w2 are the widths of their signals (peaks) at the base line.  
  
Table S2 (Continued) 












(1:1:1, v/v/v) + 
10mM NH4OAc + 
0.1% formic acid 
J: 
MeOH/IPA/ACN 
(1:1:1, v/v/v) + 
10mM NH4OAc + 
0.1% ammonium hydroxyde 
K: 
MeOH/IPA/ACN 
(1:1:1, v/v/v) + 
10mM NH4OAc + 
0.25% ammonium hydroxyde 
 k1 k2 α RS k1 k2 α RS k1 k2 α RS k1 k2 α RS k1 k2 α RS 
R/S(±)-Aminorex 0.94 0.94 1.00 0.80 0.94 0.94 1.00 1.10 - - - - 0.94 0.94 1.00 1.20 0.94 0.94 1.00 1.10 
R/S(±)-Carboxyibuprofen - - - - - - - - - - - - - - - - - - - - 
R/S(±)-Carprofen - - - - - - - - - - - - - - - - - - - - 
R/S(±)-Cetirizine  - - - - - - - - - - - - - - - - - - - - 
1S,2S-(+)-Chloramphenicol + 
1R,2R-(-)-Chloramphenicol 
- - - - 0.94 0.94 1.00 0.75 0.94 0.94 1.00 0.78 0.94 0.94 1.00 0.61 - - - - 
R/S(±)-3-N-Dechloroethyl 
ifosfamide  
0.94 0.95 1.01 4.13 0.94 0.95 1.01 7.12 0.94 0.5 1.01 5.93 0.94 0.95 1.01 5.10 0.94 0.95 1.01 4.31 
S-(+)-O-Desmethylnaproxen - - - - - - - - - - - - - - - - - - - - 
R/S(±)-Dihydroketoprofen - - - - - - - - - - - - - - - - - - - - 
R/S(±)-Fenoprofen - - - - - - - - - - - - - - - - - - - - 
R/S(±)-Fexofenadine  - - - - - - - - - - - - - - - - - - - - 
R/S(±)-Flurbiprofen 0.94 0.94 1.00 0.72 0.94 0.94 1.00 1.00 0.93 0.93 1.00 1.10 0.94 0.94 1.00 1.22 0.94 0.94 1.00 1.10 
R/S(±)-2-Hydroxyibuprofen 0.94 0.94 1.00 0.70 0.94 0.94 1.00 1.00 0.94 0.94 1.00 0.95 0.94 0.94 1.00 0.84 0.94 0.94 1.00 0.95 
R/S(±)-Ibuprofen - - - - - - - - -a -a -a -a - - - - - - - - 
R/S(±)-Ifosfamide  0.93 0.94 1.00 1.60 0.93 0.94 1.01 1.90 0.93 0.94 1.01 2.32 0.93 0.94 1.01 2.16 0.93 0.94 1.01 1.70 
R/S(±)-Imazalil - - - - - - - - - - - - - - - - - - - - 
R/S(±)-Indoprofen - - - - - - - - - - - - - - - - - - - - 
R/S(±)-Ketoprofen - - - - - - - - - - - - - - - - - - - - 
R/S(±)-Naproxen - - - - - - - - - - - - - - - - - - - - 
R/S(±)-Ofloxacin  - - - - - - - - - - - - - - - - -a -a -a -a 
R/S(±)-Omeprazole  0.96 0.96 1.00 0.72 0.96 0.96 1.00 0.95 0.96 0.96 1.00 0.95 0.96 0.96 1.00 0.96 0.96 0.96 1.00 1.17 
R/S(±)-Phenylpropionic acid  - - - - - - - - -a -a -a -a - - - - - - - - 
R/S(±)-Praziquantel 0.96 0.96 1.00 1.80 0.96 0.96 1.01 1.65 0.96 0.96 1.01 1.89 0.96 0.96 1.01 2.15 0.96 0.96 1.01 1.60 
R/S(±)-Tetramisole  0.93 0.94 1.00 0.89 0.94 0.94 1.00 0.98 0.94 0.94 1.00 1.00 0.93 0.94 1.00 1.04 0.94 0.94 1.00 1.00 
MeOH: methanol; ACN: acetonitrile; IPA: isopropanol; NH4OAc: ammonium acetate; - : no resolution; 
ano peak; k1: retention factor of the first eluted peak; k2: retention factor of the second eluted peak; α: selectivity 
factor; RS: resolution 
k’=(tR-t0)/t0  where tR is the retention time of each enantiomer (first or second) and t0 is the retention time of an unretained compound. 
α=k’2/k’1   where k’2 and k’1 are the capacity factors of the second and first eluting enantiomers, respectively.  
Rs=2(tR2-tR1)/(w1+w2)  where tR1 and tR2 are the retention times of the first and the second eluting enantiomers, respectively, and w1 and w2 are the widths of their signals (peaks) at the base line. 
  
Table S3 
Chromatographic parameters for each cPAC obtained under different mobile phase composition with CEL CSP  











(1:1, v/v) + 
0.1% formic acid 
D: 
IPA/ACN 
(1:1, v/v) + 
0.1% ammonium hydroxyde 
 k1 k2 α RS k1 k2 α RS k1 k2 α RS k1 k2 α RS 
R/S(±)-Aminorex 0.95 0.96 1.00 1.88 0.95 0.95 1.00 1.00 0.96 0.96 1.00 1.05 0.95 0.95 1.00 0.90 
R/S(±)-Cetirizine  - - - - - - - - - - - - - - - - 
1S,2S-(+)-Chloramphenicol + 
1R,2R-(-)-Chloramphenicol 
0.93 0.94 1.00 0.96 0.94 0.94 1.00 1.05 0.94 0.94 1.00 1.00 -a -a -a -a 
R/S(±)-3-N-Dechloroethylifosfamide  0.94 0.94 1.00 1.70 0.94 0.94 1.00 1.63 0.95 0.95 1.00 1.82 0.93 0.94 1.00 2.32 
R/S(±)-Fexofenadine  - - - - - - - - - - - - - - - - 
R/S(±)-Ifosfamide  - - - - - - - - - - - - 0.94 0.94 1.00 0.42 
R/S(±)-Imazalil 0.93 0.93 1.00 0.98 - - - - 0.94 0.94 1.00 1.04 - - - - 
R/S(±)-Indoprofen - - - - - - - - - - - - - - - - 
R/S(±)-Ketoprofen - - - - - - - - - - - - - - - - 
R/S(±)-Ofloxacin  0.96 0.96 1.00 0.60 0.97 0.97 1.00 1.20 - - - - 0.96 0.97 1.01 2.43 
R/S(±)-Omeprazole  0.95 0.96 1.01 2.40 0.95 0.96 1.01 2.84 0.95 0.96 1.01 3.10 0.95 0.96 1.00 1.00 
R/S(±)-Praziquantel 0.95 0.96 1.01 2.75 0.95 0.96 1.01 2.32 0.95 0.96 1.01 2.30 0.96 0.97 1.01 2.95 






10 mM NH4OAc 
G: 
MeOH + 
0.1% ammonium hydroxyde 
H: MeOH/IPA/ACN 
(1:1:1, v/v/v) + 
10mM NH4OAc + 
0.1% ammonium hydroxyde 
 k1 k2 α RS k1 k2 α RS k1 k2 α RS k1 k2 α RS 
R/S(±)-Aminorex 0.95 0.95 1.00 0.90 0.95 0.95 1.00 1.85 0.95 0.95 1.00 1.80 0.95 0.95 1.00 1.71 
R/S(±)-Cetirizine  - - - - - - - - - - - - - - - - 
1S,2S-(+)-Chloramphenicol + 
1R,2R-(-)-Chloramphenicol 
0.93 0.93 1.00 1.03 0.93 0.93 1.00 1.00 0.93 0.93 1.00 1.00 0.93 0.94 1.00 1.00 
R/S(±)-3-N-Dechloroethylifosfamide  0.93 0.94 1.00 1.20 0.93 0.94 1.00 1.10 0.93 0.94 1.00 1.38 0.94 0.94 1.00 1.45 
R/S(±)-Fexofenadine  - - - - - - - - - - - - - - - - 
R/S(±)-Ifosfamide  0.93 0.93 1.00 0.40 0.93 0.93 1.00 0.40 0.93 0.93 1.00 0.40 - - - - 
R/S(±)-Imazalil - - - - 0.93 0.93 1.00 0.80 0.93 0.93 1.00 0.72 0.93 0.93 1.00 0.90 
R/S(±)-Indoprofen - - - - - - - - - - - - - - - - 
R/S(±)-Ketoprofen - - - - - - - - - - - - - - - - 
R/S(±)-Ofloxacin  -a -a -a -a - - - - - - - - 0.96 0.97 1.00 2.00 
R/S(±)-Omeprazole  0.95 0.96 1.01 3.44 0.95 0.96 1.01 2.80 0.95 0.96 1.01 3.20 0.95 0.96 1.01 2.10 
R/S(±)-Praziquantel 0.96 0.96 1.01 2.27 0.96 0.96 1.01 2.40 0.96 0.96 1.01 2.30 0.96 0.96 1.01 2.30 
R/S(±)-Tetramisole  0.95 0.95 1.00 0.80 0.94 .95 1.01 1.90 0.94 0.95 1.01 1.42 0.94 0.95 1.01 1.73 
MeOH: methanol; ACN: acetonitrile; IPA: isopropanol; NH4OAc: ammonium acetate; - : no resolution; 
ano peak; k1: retention factor of the first eluted peak; k2: retention factor of the second eluted peak; α: selectivity 
factor; RS: resolution 
  
Table S4 
Linearity and range and inter- and intra-day precision (RSD %) of the studied cPACs with the AMY CSP 












 (μg L-1) r2 D1 D2 D3 D1 D2 D3 D1 D2 D3 D1 D2 D3 
Aminorex E1  0.83 – 500 0.999 2.5 3.6 15.6 2.7 2.9 7.7 3.1 1.9 3.3 0.2 2.7 6.1 31.9 41.2 36.5 35.9 
Aminorex E2  0.83 – 500 0.999 0.1 5.4 2.0 3.0 1.8 2.5 4.9 1.4 1.7 1.9 3.4 1.8 18.4 20.5 25.3 20.1 
R/S(±)-Carboxyibuprofen 408 – 4000 0.999 - - - - - - - - - 4.8 2.3 5.6 - - - 8.4 
Carprofen E1  168 – 500 0.979 - - - - - - - - - 6.8 6.1 9.5 - - - 14.3 
Carprofen E2  168 – 500 0.980 - - - - - - - - - 7.4 3.4 8.5 - - - 10.3 
R/S(±)-Cetirizine 3.33 – 500 0.997 11.4 15.2 1.1 3.3 8.0 4.4 6.4 2.2 3.3 5.1 1.0 4.6 9.7 15.6 14.9 16.7 
1S,2S-(+)-Chloramphenicol 16.7 – 500 0.998 - - - 4.5 4.9 4.1 5.7 5.0 1.6 5.1 1.7 2.6 - 9.7 4.7 6.0 
1R,2R-(-)-Chloramphenicol 16.9 – 500 0.998 - - - 7.0 6.8 0.8 4.9 1.1 4.3 3.7 4.6 4.6 - 9.2 3.7 4.8 
3-N-Dechloroethylifosfamide E1  0.17 – 50 0.998 2.7 3.9 n.a. 2.3 1.9 n.a. 6.9 1.5 n.a. 3.2 2.2 n.a. 63.9 60.1 69.0 68.6 
3-N-Dechloroethylifosfamide E2  0.83 – 125 0.998 0.9 10.0 4.8 2.4 3.2 2.2 0.5 0.9 2.1 3.5 0.6 1.5 14.1 11.4 9.8 16.4 
S-(+)-O-Desmethylnaproxen 173.5 – 1000 0.997 - - - - - - 7.5 16.1 2.9 4.2 2.1 3.2 - - 7.4 8.9 
R/S(±)-Dihydroketoprofen 33.3 – 4000 0.998 - - - 3.6 9.0 4.9 2.9 3.3 4.7 0.8 4.1 1.0 - 6.4 7.2 7.2 
Fenoprofen E1  171 – 4000 0.999 - - - - - - - -  15.3 9.5 8.7 - - - 9.0 
Fenoprofen E2  171 – 4000 0.994 - - - - - - - -  11.8 3.9 9.2 - - - 9.5 
R/S(±)-Fexofenadine  16.9 – 500 0.997 - - - 2.9 5.8 3.5 2.3 2.3 3.2 4.5 3.2 0.8 - 8.7 5.6 8.1 
Flurbiprofen E1  83.8 – 2000 0.996 - - - - - - 9.1 22.0 n.a. 5.6 14.3 n.a. - - 5.9 20.0 
Flurbiprofen E2  83.8 – 2000 0.996 - - - - - - 7.6 7.3 5.0 5.3 5.2 5.5 - - 5.3 3.3 
2-Hydroxyibuprofen E1  163.5 – 500 0.999 - - - - - - 8.2 7.6 3.3 2.6 1.9 3.7 - - 4.9 6.2 
2-Hydroxyibuprofen E2  163.5 – 500 0.997 - - - - - - 9.0 3.4 3.4 2.8 2.3 1.3 - - 6.9 7.9 
R-(-)-Ibuprofen 415 – 2000 0.997 - - - - - - - - - 9.2 10.4 7.1 - - - 13.0 
S-(+)-Ibuprofen 415 – 2000 0.993 - - - - - - - - - 11.0 4.3 6.9 - - - 12.3 
Ifosfamide E1  0.17 – 125 0.998 1.3 2.4 4.3 5.2 0.3 2.5 3.4 3.6 0.4 2.1 1.6 1.3 5.8 6.4 5.2 4.8 
Ifosfamide E2  0.17 – 125 0.995 3.6 5.1 5.5 3.1 4.9 3.2 3.6 3.0 2.1 3.0 1.4 2.4 7.4 8.4 13.2 12.0 
R/S(±)-Imazalil 0.87 – 1000 0.999 3.7 1.8 1.3 2.9 2.0 2.0 1.9 2.5 0.3 2.1 1.0 0.7 11.8 12.3 10.6 12.6 
Indoprofen E1  0.85 – 250 0.998 13.6 4.9 9.0 8.7 2.0 3.1 6.8 4.5 1.6 3.0 3.1 0.4 11.0 9.1 10.9 5.3 
Indoprofen E2  0.85 – 500 0.999 11.7 9.0 8.2 5.7 11.8 6.1 5.0 5.7 4.5 7.2 4.2 1.5 11.6 13.6 15.0 10.8 
R/S(±)-Ketoprofen 33.2 – 1000 0.995 - - - 17.5 11.8 12.6 0.7 4.0 6.3 4.1 10.8 14.6 - 32.4 43.9 28.7 
R-(-)-Naproxen 84.3 – 2000 0.998 - - - 5.6 7.0 7.5 9.1 14.6 6.5 2.7 5.0 3.3 - 9.2 11.5 5.1 
S-(+)-Naproxen 84.3 – 2000 0.999 - - - 7.3 9.2 3.1 6.5 6.6 1.9 4.0 5.4 2.6 - 11.5 7.5 6.9 
R/S(±)-Ofloxacin  32.8 – 1000 0.995 - - - 6.7 6.4 5.8 1.6 5.8 1.3 2.1 2.3 4.1 - 24.6 20.6 23.3 
Omeprazole E1  0.82 – 125 0.998 7.9 4.0 3.8 0.8 1.7 3.3 3.5 5.7 1.2 2.6 2.9 1.1 21.4 12.9 14.6 14.3 
Omeprazole E2  0.82 – 250 0.997 3.3 2.8 4.3 7.7 1.3 2.0 2.1 3.6 0.9 4.4 1.6 1.7 5.2 11.6 12.2 8.5 
R/S(±)-Phenylpropionic acid  741.3 – 4000 0.999 - - - - - - - - - 12.6 3.4 6.7 - - - 9.6 
Praziquantel E1  0.83 – 50 0.996 6.9 3.5 7.3 2.0 3.5 1.1 1.5 1.6 2.5 1.6 0.2 2.0 8.3 3.8 6.6 2.8 
Praziquantel E2  0.83 – 50 0.998 3.6 6.2 7.0 3.1 1.8 4.6 0.6 2.9 3.4 1.2 0.3 0.9 7.7 5.8 4.4 5.1 
R-(+)-Tetramisole  0.83 – 500 0.998 4.8 6.4 4.8 1.7 1.0 2.5 6.4 2.5 4.8 2.2 4.0 3.7 7.5 4.9 5.7 4.6 
S-(-)-Tetramisole  0.83 – 500 0.997 2.4 1.2 8.9 5.1 2.6 4.0 9.8 2.4 4.0 3.8 2.3 5.6 10.5 6.8 6.1 7.2 
D1, D2, D3: day 1, 2 and 3; n.a.: not available 
  
Table S5 
Linearity and range and inter- and intra-day precision (RSD %) of the studied cPACs with the CEL CSP 
 Linearity  Intra-day precision (% RSD) Inter-day precision (% RSD) 
Compound range  0.5 (μg L









(μg L-1)  (μg L-1) r2 D1 D2 D3 D1 D2 D3 D1 D2 D3 D1 D2 D3 D1 D2 D3 
Aminorex E1 0.83 – 500 0.998 14.5 11.8 6.0 6.2 3.0 5.8 0.9 4.3 0.9 3.2 0.4 2.6 0.5 2.5 1.2 16.7 12.1 11.3 10.1 11.7 
Aminorex E2 0.83 – 500 0.996 3.9 18.4 7.8 3.0 1.6 2.7 1.9 2.9 1.6 2.0 1.7 1.6 1.5 2.4 2.6 14.6 9.8 11.5 10.3 10.3 
R/S(±)-Cetirizine 16.4 – 250 0.997 - - - 20.8 18.5 18.6 2.7 4.2 1.1 4.3 3.4 1.7 3.0 3.7 2.4 - 22.8 21.9 19.1 17.9 
3-N-Dechloroethylifosfamide E1 0.83 – 125 0.996 11.2 13.8 7.9 2.1 0.5 1.3 1.6 2.1 0.6 5.5 0.7 0.9 0.7 2.1 0.4 13.2 1.4 11.9 5.2 8.3 
3-N-Dechloroethylifosfamide E2 0.83 – 125 0.999 13.8 6.3 9.5 5.2 6.3 2.9 3.4 1.0 2.9 1.1 2.3 1.7 1.0 2.9 0.8 10.3 8.4 3.5 1.7 2.4 
R/S(±)-Fexofenadine 1.69 – 500 0.999 19.3 17.6 16.9 9.5 4.4 2.5 3.3 4.0 2.0 2.2 2.4 1.7 4.4 1.5 1.5 23.1 14.3 17.3 15.8 14.1 
R/S(±)-Ifosfamide 1.69 – 100 0.999 7.3 3.6 5.2 4.5 8.3 3.4 0.8 1.6 3.6 1.3 1.4 0.6 0.9 0.7 1.2 6.7 8.8 3.2 5.1 4.9 
Imazalil E1 1.74 – 500 0.998 9.4 13.2 18.3 6.5 5.1 9.2 5.4 1.8 3.0 1.2 2.8 5.8 3.8 1.5 1.8 21.5 17.1 13.3 14.4 13.0 
Imazalil E2 1.74 – 250 0.997 24.0 24.5 13.5 7.7 17.7 6.5 4.3 3.3 6.7 3.5 1.4 1.8 4.4 1.1 1.2 23.6 16.8 13.0 14.4 12.2 
Indoprofen E1 1.69 – 500 0.998 10.9 8.9 n.a. 2.4 8.5 2.4 8.6 6.6 2.6 7.2 4.2 5.6 1.0 2.5 4.1 18.5 7.8 12.8 12.3 6.9 
Indoprofen E2 1.69 – 250 0.997 14.2 8.0 n.a. 2.5 4.6 4.9 1.7 6.0 4.4 1.9 3.8 0.5 1.9 1.5 1.2 21.4 14.3 15.5 13.7 11.9 
R/S(±)-Ketoprofen 16.6 – 500 0.998 - - - 2.1 4.9 7.4 3.3 1.1 1.2 4.1 3.1 3.9 0.6 1.5 1.1 - 11.5 12.5 11.9 11.0 
Ofloxacin E1 16.4 – 500 0.997 - - - - - - 13.5 13.9 14.3 4.1 10.0 6.9 2.0 1.8 2.6 - - 15.5 14.0 13.1 
Ofloxacin E2 16.4 – 250 0.996 - - - - - - 9.3 6.3 13.1 8.4 13.5 6.5 4.1 5.8 4.2 - - 18.3 13.9 13.8 
Omeprazole E1 1.63 – 500 0.995 14.2 12.3 n.a. 2.0 4.1 6.0 7.1 5.3 1.3 2.5 5.4 2.8 2.0 2.0 1.8 29.6 14.0 17.0 15.5 16.4 
Omeprazole E2 1.63 –500 0.993 9.7 10.4 n.a. 5.3 2.0 4.7 3.3 1.3 3.3 6.6 2.2 1.0 3.9 1.2 2.5 30.1 9.7 15.0 15.2 15.0 
Praziquantel E1 1.67 – 500 0.999 11.5 n.a. n.a. 2.7 3.1 2.4 1.8 2.1 2.7 0.7 1.3 0.6 1.2 0.4 0.7 11.5 7.1 9.7 10.0 8.7 
Praziquantel E2 1.67 – 250 0.997 14.0 n.a. n.a. 4.3 9.8 5.5 4.1 5.3 2.6 0.9 6.3 1.0 2.2 2.7 2.8 14.0 8.0 10.9 9.3 7.5 
R-(+)-Tetramisole 0.83 – 250 0.994 4.6 11.7 16.9 0.5 6.1 6.4 4.7 0.8 4.8 4.7 2.6 2.3 2.3 2.2 3.9 12.3 5.5 10.4 9.6 11.2 
S-(-)-Tetramisole 0.83 – 500 0.994 11.4 13.3 3.0 8.2 7.9 7.9 1.6 2.3 1.8 5.6 3.1 1.1 2.1 2.2 5.8 17.0 12.1 10.0 7.7 6.6 




Recovery (%), intra-day precision (RSD %) and enantiomeric fraction in influent wastewater with the AMY CSP 

















Aminorex E1a 102.4 (10.3) 45.5 (11.3) 0.38 ± 0.01 97.3 (n.a.) 79.0 (2.5) 0.49 ± 0.10 125.1 (6.4) 65.2 (3.7) 0.48 ± 0.01 
Aminorex E2a 98.1 (8.9) 34.9 (2.2)  97.3 (7.1) 40.6 (5.1)  95.2 (9.0) 40.5 (5.5)  
R/S(±)-Carboxyibuprofenb - -  - -  86.8 (27.4) 37.8 (17.7)  
Carprofen E1c - - - 133.3 (8.2) 113.8 (1.7) 0.46 ± 0.01 127.4 (3.4) 111.4 (5.4) 0.46 ± 0.01 
Carprofen E2c - -  171.3 (3.6) 143.7 (0.3)  124.8 (4.1) 102.5 (5.9)  
R/S(±)-Cetirizinee -h -h  -h -h  -h -h  
1S,2S-(+)-Chloramphenicolb 117.8 (18.0) 97.8 (10.0) 0.59 ± 0.04 115.0 (5.1) 91.3 (4.9) 0.60 ± 0.03 110.2 (15.2) 84.2 (2.1) 0.55 ± 0.01 
1R,2R-(-)-Chloramphenicolb 109.6 (2.8) 80.4 (3.1)  111.3 (1.4) 77.0 (3.3)  118.8 (6.4) 80.5 (3.1)  
3-N-Dechloroethylifosfamide E1d 167.6 (n.a.) 110.0 (n.a.) 0.50 ± 0.05 108.4 (20.0) 101.5 (19.9) 0.50 ± 0.05 74.2 (n.a.) 45.4 (n.a.) 0.50 ± 0.05 
3-N-Dechloroethylifosfamide E2d 78.7 (3.7) 43.8 (7.7)  77.6 (11.2) 44.7 (8.1)  91.5 (13.3) 39.4 (3.9)  
S-(+)-O-Desmethylnaproxenb - -  87.9 (7.1) 60.6 (11.4)  76.8 (5.3) 51.9 (8.3)  
R/S(±)-Dihydroketoprofenb 58.7 (15.5) 62.0 (19.9)  98.3 (9.2) 70.0 (5.7)  103.0 (8.4) 70.0 (3.8)  
Fenoprofen E1b - - - 89.7 (15.1) 78.7 (11.7) 0.46 ± 0.06 89.7 (24.1) 80.4 (14.0) 0.42 ± 0.08 
Fenoprofen E2b - -  95.1 (15.4) 62.3 (14.6)  91.8 (11.6) 63.0 (8.7)  
R/S(±)-Fexofenadinee 51.8 (2.3) 74.7 (9.7)  103.1 (4.8) 88.7 (7.5)  106.9 (9.9) 83.4 (7.7)  
Flurbiprofen E1b - - - -g -g - -g -g - 
Flurbiprofen E2b - -  76.1 (8.0) 52.6 (11.3)  75.8 (5.7) 51.5 (10.2)  
2-Hydroxyibuprofen E1b - - - 160.0 (n.a.) 77.0 (22.8) 0.22 ± 0.01 120.2 (26.0) 82.4 (34.3) 0.25 ± 0.02 
2-Hydroxyibuprofen E2b - -  90.3 (25.0) 116.2 (11.5)  96.3 (n.a.) 82.4 (34.3)  
R-(-)-Ibuprofenc - - - 88.4 (4.3) 82.2 (5.7) 0.75 ± 0.01 117.4 (2.9) 101.8 (8.3) 0.62 ± 0.02 
S-(+)-Ibuprofenc - -  81.7 (1.7) 77.9 (7.7)  67.8 (28.7) 48.6 (36.0)  
Ifosfamide E1d 90.6 (15.5) 54.9 (3.9) 0.54 ± 0.03 99.7 (4.4) 57.7 (2.7) 0.57 ± 0.01 88.7 (7.3) 56.1 (5.5) 0.49 ± 0.04 
Ifosfamide E2d 99.5 (4.4) 55.5 (4.5)  87.9 (4.8) 50.7 (2.9)  112.9 (9.8) 48.7 (0.8)  
R/S(±)-Imazalild 66.3 (9.4) 36.4 (5.3)  98.5 (3.0) 57.1 (4.3)  89.4 (11.9) 56.6 (7.1)  
Indoprofen E1e 99.0 (15.6) 66.2 (6.8) 0.53 ± 0.01 106.9 (3.8) 71.2 (2.3) 0.53 ± 0.01 94.7 (3.8) 66.6 (4.8) 0.53 ± 0.001 
Indoprofen E2e 101.8 (11.6) 68.3 (5.6)  94.9 (4.9) 63.3 (4.5)  98.3 (5.3) 69.1 (6.0)  
R/S(±)-Ketoprofenf -h -h  -h -h  -h -h  
R-(-)-Naproxenb - - - 108.4 (8.6) 57.8 (3.8) 0.80 ± 0.01 104.3 (16.2) 55.1 (6.6) 0.74 ± 0.02 
S-(+)-Naproxenb - -  94.6 (4.5) 96.6 (16.1)  97.1 (13.7) 70.8 (7.5)  
R/S(±)-Ofloxacind 78.2 (6.2) 49.3 (18.1)  36.6 (13.7) 20.9 (11.0)  45.8 (15.2) 19.6 (5.9)  
Omeprazole E1e 19.1 (9.4) 14.8 (7.0) 0.46 ± 0.03 17.2 (16.3) 11.7 (17.0) 0.48 ± 0.01 7.3 (17.2) 5.3 (20.5) 0.48 ± 0.02 
Omeprazole E2e 22.9 (5.3) 15.3 (14.8)  19.3 (21.2) 12.9 (21.8)  8.6 (22.7) 6.1 (25.8)  
R/S(±)-Phenylpropionic acidc - -  54.8 (12.9) 56.0 (4.7)  70.6 (25.8) 56.4 (2.2)  
Praziquantel E1e 99.2 (4.9) 66.9 (7.4) 0.52 ± 0.01 94.1 (5.7) 62.9 (4.4) 0.48 ± 0.02 92.0 (2.8) 64.7 (4.6) 0.48 ± 0.01 
Praziquantel E2e 98.2 (7.2) 81.1 (2.7)  101.4 (0.9) 85.3 (2.3)  103.2 (5.1) 80.3 (4.7)  
R-(+)-Tetramisolea 76.1 (4.4) 36.3 (7.4) 0.54 ± 0.001 98.0 (10.9) 44.9 (1.1) 0.55 ± 0.04 104.1 (7.8) 48.3 (2.6) 0.56 ± 0.02 
S-(-)-Tetramisolea 80.5 (5.8) 27.8 (5.2)  84.7 (7.2) 35.3 (2.7)  88.5 (2.8) 37.7 (2.3)  





Recovery (%), intra-day precision (RSD %) and enantiomeric fraction in effluent wastewater with the AMY CSP 

















Aminorex E1a 102.0 (8.3) 82.8 (9.2) 0.46 ± 0.04 115.7 (10.5) 100.0 (8.9) 0.49 ± 0.04 92.7 (2.8) 84.3 (3.8) 0.40 ± 0.02 
Aminorex E2a 72.8 (16.0) 52.7 (13.5)  82.9 (4.1) 65.5 (0.3)  80.9 (5.2) 72.0 (2.5)  
R/S(±)-Carboxyibuprofenb - -  107.5 (9.4) 89.5 (6.6)  89.7 (6.6) 85.6 (6.9)  
Carprofen E1c - - - 86.3 (4.7) 49.0 (6.5) 0.52 ± 0.02 112.6 (9.6) 69.9 (11.1) 0.53 ± 0.02 
Carprofen E2c - -  71.5 (10.3) 42.9 (5.2)  74.6 (14.8) 44.8 (11.1)  
R/S(±)-Cetirizinee -h -h  -h -h  -h -h  
1S,2S-(+)-Chloramphenicolb 109.3 (3.4) 74.8 (14.7) 0.58 ± 0.03 99.8 (3.2) 76.6 (5.9) 0.50 ± 0.02 103.3 (5.7) 81.9 (3.6) 0.53 ± 0.04 
1R,2R-(-)-Chloramphenicolb 93.6 (9.1) 79.6 (10.7)  95.1 (6.4) 78.8 (1.8)  86.4 (14.4) 82.2 (6.7)  
3-N-Dechloroethylifosfamide E1d 29.8 (7.8) 25.5 (5.8) 0.50 ± 0.05 37.0 (25.3) 29.7 (23.5) 0.50 ± 0.05 63.3 (19.6) 55.3 (22.9) 0.50 ± 0.05 
3-N-Dechloroethylifosfamide E2d 58.1 (18.7) 44.6 (39.6)  29.0 (0.1) 22.1 (0.8)  52.4 (20.7) 50.3 (10.6)  
S-(+)-O-Desmethylnaproxenb - -  93.6 (5.7) 77.3 (2.3)  83.0 (9.4) 79.0 (1.9)  
R/S(±)-Dihydroketoprofenb 35.1 (20.9) 43.9 (12.5)  91.6 (3.3) 77.8 (3.4)  87.1 (5.7) 84.4 (4.5)  
Fenoprofen E1b - - - 102.7 (1.8) 81.3 (6.0) 0.52 ± 0.03 112.6 (5.1) 86.6 (5.7) 0.57 ± 0.001 
Fenoprofen E2b - -  104.5 (12.6) 84.3 (17.7)  100.7 (6.1) 91.0 (6.0)  
R/S(±)-Fexofenadinee -h -h  60.8 (14.1) 63.8 (4.7)  72.7 (3.8) 75.1 (4.3)  
Flurbiprofen E1b - - - -g -g - 88.4 (23.0) 71.3 (18.1) 0.60 ± 0.02 
Flurbiprofen E2b - -  66.6 (0.7) 55.1 (5.2)  64.6 (18.3) 61.4 (13.9)  
2-Hydroxyibuprofen E1b - - - -h -h - 22.6 (12.2) 64.4 (7.6) 0.49 ± 0.02 
2-Hydroxyibuprofen E2b - -  -h -h  - 33.8 (7.1)  
R-(-)-Ibuprofenc - - - 85.5 (12.6) 54.8 (5.5) 0.50 ± 0.03 98.6 (9.4) 58.4 (3.9) 0.50 ± 0.03 
S-(+)-Ibuprofenc - -  85.8 (10.0) 50.8 (7.0)  97.1 (1.6) 59.1 (3.3)  
Ifosfamide E1d 89.0 (1.2) 66.0 (6.0) 0.52 ± 0.02 100.2 (2.0) 77.0 (0.8) 0.51 ± 0.03 89.9 (7.1) 80.3 (3.1) 0.54 ± 0.04 
Ifosfamide E2d 92.1 (7.6) 66.1 (10.3)  95.0 (12.5) 77.4 (0.8)  86.8 (7.4) 81.7 (2.0)  
R/S(±)-Imazalild 76.8 (0.3) 56.9 (6.0)  87.3 (4.1) 67.0 (2.8)  78.7 (8.1) 70.3 (3.9)  
Indoprofen E1e 79.1 (8.8) 61.3 (10.3) 0.54 ± 0.02 88.1 (5.5) 71.7 (2.2) 0.52 ± 0.01 89.2 (8.5) 78.0 (4.7) 0.53 ± 0.001 
Indoprofen E2e 82.4 (2.2) 64.2 (1.9)  95.7 (8.2) 77.9 (3.9)  90.9 (9.1) 79.2 (3.2)  
R/S(±)-Ketoprofenf -h -h  -h -h  66.3 (10.0) 66.2 (5.5)  
R-(-)-Naproxenb - - - -h -h - 46.9 (6.8) 67.4 (6.9) - 
S-(+)-Naproxenb - -  -h -h  -h -h  
R/S(±)-Ofloxacind 70.3 (34.2) 49.8 (17.2)  37.8 (10.6) 30.5 (1.3)  29.7 (15.0) 27.7 (12.3)  
Omeprazole E1e <10 <10 - <10 <10 - <10 <10 - 
Omeprazole E2e <10 <10  <10 <10  <10 <10  
R/S(±)-Phenylpropionic acidc . .  87.9 (3.2) 50.0 (4.0)  70.3 (15.1) 39.1 (15.9)  
Praziquantel E1e 86.4 (9.1) 68.0 (8.8) 0.50 ± 0.04 95.0 (3.7) 77.4 (2.4) 0.50 ± 0.01 91.6 (8.4) 80.0 (2.4) 0.51 ±0.01 
Praziquantel E2e 94.0 (13.3) 71.6 (13.3)  90.4 (4.8) 78.1 (1.3)  86.9 (4.1) 82.0 (2.7)  
R-(+)-Tetramisolea 25.3 (32.4) 32.4 (27.3) 0.54 ± 0.01 87.9 (8.1) 77.6 (6.1) 0.53 ± 0.03 85.4 (3.3) 78.7 (5.7) 0.50 ±0.03 
S-(-)-Tetramisolea 51.8 (0.2) 43.4 (7.6)  86.9 (5.2) 69.5 (1.1)  89.6 (8.3) 80.3 (1.2)  





Recovery (%), intra-day precision (RSD %) and enantiomeric fraction in influent wastewater with the CEL CSP 




















107.6 (7.7) 48.3 (0.8) 0.52 ± 0.01 106.9 (13.1) 49.8 (4.2) 0.51 ± 0.001 
Aminorex E2a 
86.2 (13.5) 45.8 
(1.2) 
 98.6 (11.7) 44.1 (4.5)  101.2 (12.8) 47.1 (5.1)  
R/S(±)-Cetirizinea -e -e  -e -e  -e -e  
3-N-Dechloroethylifosfamide E1b 




89.0 (7.5) 52.0 (9.0) 0.50 ± 0.001 86.0 (13.3) 45.4 (4.1) 0.50 ± 0.01 
3-N-Dechloroethylifosfamide E2b 
90.5 (5.4) 52.5 
(5.5) 
 83.5 (6.1) 48.7 (7.8)  85.1 (9.6) 45.0 (2.7)  
R/S(±)-Fexofenadinea -e -e  85.1 (6.4) 59.8 (3.5)  102.1 (16.6) 56.0 (5.6)  
R/S(±)-Ifosfamideb 
97.4 (7.4) 55.3 
(4.2) 
 90.3 (1.3) 52.5 (2.9)  99.7 (5.7) 52.8 (4.7)  
Imazalil E1c 




102.0 (7.6) 63.4 (5.3) 0.50 ± 0.01 99.9 (9.8) 60.4 (6.9) 0.49 ± 0.01 
Imazalil E2c 
88.9 (7.0) 57.6 
(12.0) 
 101.1 (9.0) 62.5 (6.2)  100.2 (9.0) 60.5 (6.0)  
Indoprofen E1a 




91.9  (18.2) 40.6 (11.1) 0.37 ± 0.03 85.5 (12.2) 39.7 (5.2) 0.38 ± 0.01 
Indoprofen E2a 
145.4 (2.3) 70.9 
(10.7) 
 128.8 (2.6) 59.5 (0.8)  127.8 (14.1) 59.2 (3.6)  
R/S(±)-Ketoprofenc 
77.9 (19.6) 62.4 
(1.1) 
 81.9 (6.4) 52.1 (3.4)  93.5 (6.1) 57.0 (4.2)  
S-(-)-Ofloxacina -e -e - 50.2 (19.9) 50.4 (11.8) 0.34 ± 0.02 61.6 (4.1) 35.6 (7.2) 0.45 ± 0.04 
R-(+)-Ofloxacina -e -e  78.1 (5.2) 47.8 (3.3)  88.9 (14.4) 47.6 (4.5)  
Omeprazole E1a <10 <10 - <10 <10 - <10 <10 - 
Omeprazole E2a <10 <10  <10 <10  <10 <10  
Praziquantel E1a 




75.7 (8.2) 32.8 (1.4) 0.44 ± 0.02 73.0 (13.0) 33.8 (2.5) 0.40 ± 0.03 
Praziquantel E2a 
109.6 (8.1) 63.6 
(12.1) 
 89.7 (4.2) 55.5 (2.6)  99.4 (15.1) 53.4 (3.2)  




91.5 (11.3) 66.5 (5.4) 0.51 ± 0.02 88.6 (8.6) 66.0 (4.2) 0.49 ± 0.03 
S-(-)-Tetramisoled 64.2 (9.8) 49.6 
(9.8) 
 80.9 (1.9) 48.0 (4.6)  89.8 (4.4) 41.1 (4.4)  





Recovery (%), intra-day precision (RSD %) and enantiomeric fraction in effluent wastewater with the CEL CSP 














Aminorex E1a 96.3 (1.5) 55.9 (11.6) 0.50 ± 0.01 89.7 (4.1) 66.7 (7.1) 0.49 ± 0.01 91.2 (2.5) 74.8 (8.6) 0.49 ± 0.01 
Aminorex E2a 95.1 (7.4) 55.9 (17.2)  90.8 (5.2) 67.9 (5.6)  90.8 (2.4) 74.6 (6.0)  
R/S(±)-Cetirizinea -e -e  -e -e  -e -e  
3-N-Dechloroethylifosfamide E1b 47.1 (29.0) 29.4 (22.3) 0.53 ± 0.01 28.7 (33.4) 22.1 (25.6) 0.51 ± 0.01 66.3 (12.6) 84.5 (16.2) 0.53 ± 0.02 
3-N-Dechloroethylifosfamide E2b 43.8 (36.4) 27.2 (30.1)  28.8 (28.0) 19.6 (23.1)  102.6 (5.2) 74.1 (1.6)  
R/S(±)-Fexofenadinea -e -e  63.8 (5.4) 58.1 (9.6)  92.7 (15.7) 72.8 (13.0)  
R/S(±)-Ifosfamideb 84.0 (10.2) 55.0  (8.4)  89.9 (3.2) 61.8 (3.8)  91.2 (3.0) 70.9 (4.5)  
Imazalil E1c 78.2 (1.9) 54.7 (1.1) 0.46 ± 0.001 73.6 (7.2) 57.9 (9.6) 0.48 ± 0.001 65.1 (5.1) 67.4 (9.6) 0.49 ± 0.01 
Imazalil E2c 92.9 (3.4) 65.5 (2.8)  80.9 (7.4) 63.6 (7.7)  65.2 (3.3) 68.9 (8.7)  
Indoprofen E1a 70.2 (11.4) 41.1 (20.3) 0.39 ± 0.03 74.5 (9.3) 55.6 (6.3) 0.43 ± 0.01 95.5 (2.6) 78.1 (3.7) 0.47 ± 0.01 
Indoprofen E2a 103.3 (3.2) 59.7 (7.4)  92.0 (6.1) 68.9 (6.6)  88.7 (5.6) 72.7 (6.1)  
R/S(±)-Ketoprofenc 20.0 (41.5) 29.5 (22.4)  86.3 (3.3) 69.9 (9.6)  86.2 (10.4) 85.6 (3.0)  
S-(-)-Ofloxacina - - -  75.6 (6.7) 56.4 (8.8) 0.49 ± 0.02 66.1 (10.8) 54.3 (2.4) 0.45 ± 0.05 
R-(+)-Ofloxacina - -  62.4 (12.5) 47.2 (10.0)  60.6 (9.7) 50.3 (10.8)  
Omeprazole E1a <10 <10  <10 <10  <10 <10  
Omeprazole E2a <10 <10  <10 <10  <10 <10  
Praziquantel E1a 85.1 (4.9) 51.2 (9.1) 0.45 ± 0.03 73.7 (5.2) 55.0 (5.5) 0.44 ± 0.01 84.3 (7.7) 69.2 (1.7) 0.48 ± 0.02 
Praziquantel E2a 91.4 (8.9) 68.8 (8.5)  94.6 (5.4) 73.4 (6.2)  100.9 (3.7) 77.1 (5.3)  
R-(+)-Tetramisoled 18.2 (10.8) 34.8 (5.7) 0.52 ± 0.02 78.9 (2.4) 73.6 (6.3) 0.49 ± 0.02 78.3 (4.9) 88.2 (7.0) 0.51 ± 0.01 
S-(-)-Tetramisoled 48.5 (7.5) 49.7 (11.4)  95.9 (10.1) 74.1 (4.8)  78.8 (7.0) 75.2 (10.9)  
aIS: Praziquantel-d11;bIfosfamide-d4; cKetoprofen-d3; dTetramisole-d5; ePresence in the unspiked at high concentration levels 
 
 
 
 
